Author Archives: admin


Omeros: 2 Major Catalysts On The Horizon – Seeking Alpha

Back in the thirties we were told we must collectivize the nation because the people were so poor. Now we are told we must collectivize the nation because the people are so rich. William F. Buckley Jr.

Today, we revisit a 'Tier 3' biotech stock whose stock has been under some recent pressure. However, it has two potential significant catalysts on the horizon. We update our investment case on this intriguing small-cap concern in the paragraphs below.

Omeros Corporation (OMER) is a Seattle based commercial-stage biopharmaceutical concern focused on the development of small molecule and protein therapeutics for the treatment of inflammation, complement-mediated diseases, central nervous system disorders, and immune-related diseases, including cancer. The company has one commercial asset, one late-stage candidate being evaluated for three indications, and several early and preclinical compounds. Omeros was formed in 1994 and went public in 2009, raising net proceeds of $61.8 million at $10 a share. The company completed a secondary offering at $13.10 in December 2019 following the release of positive data on its late-stage candidate, OMS721 (narsoplimab). The current market capitalization of OMER is just under $700 million.

Product:

Omidria. Omeros revenue is generated from Omidria, a phenylephrine and ketorolac intraocular solution that is approved for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and reducing postoperative pain. Omidria was launched in 2015 and in 2017 generated net revenue of $64.8 million. However, the Centers for Medicare and Medicaid Services (CMS) determined to let its separate reimbursement under Medicare Part B expire on January 1, 2018, causing sales to plummet ~90%. Fortunately for Omeros, an act of Congress circumvented the CMS and reinstated its pass-through status for two years starting October 1, 2018. Omidria sales rebounded, likely eclipsing $110 million in 2019.

The reason for the pushback from the CMS regarding Omidria has to do with the fact that its active ingredients (phenylephrine and ketorolac) have been around for decades and a similar solution can be prepared by surgeons at a fraction of Omidrias cost. Omeros continues to pursue permanent separate reimbursement for Omidria and the CMS left the door open, indicating a need to find non-opioid alternatives. However, despite the company providing evidence demonstrating Omidria use reduced the need for fentanyl by nearly 80%, the CMS own study suggested otherwise, and it declined to grant Omidria separate payment status. News of this rejection sent shares 16% lower on November 4, 2019.

The CMS continues to analyze and monitor Omidria, and Omeros will exhaust all legislative and administrative avenues to secure permanent or similar status before the September 2020 expiration, including bipartisan anti-opioid legislation that could grant Omidria separate payment status for up to an additional five years. Management remains confident in its ability to gain permanent or similar status beyond September 2020. If it does not prevail, the blow to its top line will be harsh but not likely as severe as in 2018, owing to Omidria receiving its own J-Code in October 2019, which expands separate payment across commercial Med Advantage and Medicaid insurers, as well as in the office setting.

It goes without saying that Omidrias status will alter by a number of years how fast the company will achieve cash-flow positive levels.

Pipeline:

OMS721. In the meantime, Omeros has initiated a rolling BLA for OMS721, its monoclonal antibody (MAB) targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a protein involved in the activation of the complement system, a branch of the bodys immune system that destroys and removes foreign particles and is engaged in the bodys inflammatory response. OMS721 is currently being evaluated in the treatment of three diseases that are all the result of complement system dysfunction.

The indication for which Omeros is filing a BLA is hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a multifactorial disorder induced by systemic vascular endothelial injury that can be triggered by several mechanisms during the transplant process. It occurs in ~40% of the ~60,000 patients undergoing allogenic HSCT in the U.S. and EU annually and is characterized by aggressive blood clotting usually resulting in acute renal failure. Severe cases have a mortality rate north of 90%. There are currently no approved therapies for HSCT-TMA.

That may change as the FDA was impressed enough with February 2018 interim data from OMS721s Phase 2 HSCT-TMA trial, in which median overall survival in 19 patients improved to 347 days versus the historical norm of 21 days (p<0.0001), to treat the small proof-of-concept study as registrational. Omeros released additional data on December 4, 2019, showing OMS721 demonstrated a 68% complete responder rate and a 100-day mortality rate of 19% versus the historical norm of 53% in HSCT-TMA patients who received at least four weeks of dosing. This prompted a 6% rally in shares of OMER, the trading session before the secondary offering was announced.

It should be noted that there are other candidates in the clinic for the HSCT-TMA indication, including Alexions (ALXN) already approved (for other indications) C5 inhibitor Ultomiris. However, Alexion is well behind, planning to initiate a Phase 3 trial (pending FDA feedback) in 1H20. The same can be said regarding Akari Therapeutics (AKTX) nomacopan, which plans to initiate a Phase 3 pediatric study in 1Q20. These schedules should give OMS721 a significant jump on any competition, which should have its BLA completed in 1H20. In addition to Breakthrough Therapy designation from FDA, OMS721 has Orphan drug status in both the U.S. and Europe and will likely receive a priority review from the FDA for HSCT-TMA.

OMS721's second most advanced indication is Immunoglobulin A (IGA) nephropathy, an ailment characterized by inflammation and kidney damage due to a buildup of the IgA antigen that affects 130,000150,000 people in the US and ~200,000 people in Europe with no approved remedies. After positive data from a very small Phase 2 study in which OMS721 reduced proteinuria in IgA nephropathy patients by 50-90%, Omeros finalized the particulars of a Phase 3 trial with the FDA in January 2019. The trials primary endpoint is the same: the relatively novel reduction in proteinuria levels at week 36. By obtaining approval on this endpoint (versus say renal function as measured by estimated glomerular filtration rate), it could potentially shorten the approval process by several years. Enrollment in the ~280-patient study is ongoing and accelerating. For this indication, OMS721 has received Breakthrough Therapy designation from the FDA and Orphan status in both the U.S. and EU.

To date, OMS721 has not been menaced by any significant safety or tolerability issues, which will help it in its pursuit of approval in the treatment of atypical hemolytic uremic syndrome (aHUS), a very rare disorder characterized by uncontrolled activation of the bodys complement system, manifesting itself in strokes, heart attacks, and kidney failures. Approximately 65% of patients diagnosed with aHUS die, require dialysis, or incur permanent renal damage within one year after diagnosis. The only approved treatment on the market is Alexions mAb Soliris, which has a Black Box warning due to risk of fatal infections as a result of suppression of the immune system. In most instances, patients must be immunized with a meningococcal vaccine at least two weeks prior to first administration of Soliris.

Armed with Fast Track and Orphan designations, Omeros only needs to conduct a 40-patient, single-arm (i.e., no control group), open-label Phase 3 trial to satisfy both the FDA and EMA for accelerated and full approvals, respectively. To achieve full approval in the U.S., OMS721 will need to add ~40 patients to the study. The issue confronting Omeros is that the trial began enrollment in 4Q16 and three years later management has not provided any definitive timetable regarding the trials progress, providing a frustrating connotation of accelerated approval for investors.

OMS527. Omeros other clinical asset is OMS527, which is being investigated in patients with addictions and compulsive disorders. After a successful Phase 1 study readout in 3Q19, OMS527 is expected to enter a Phase 2a trial in 2020 with a focus on nicotine addiction.

OMS906 and GPR174. The company also has assets that have demonstrated promise in the pre-clinic. OMS906 is a MASP-3 inhibitor for paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Pre-clinical research on GPR174 inhibition has displayed promise in immuno-oncology. OMS906 is expected to enter the clinic in 1H20; GPR174 inhibitors will see the clinic when the company has more resources.

On that front, Omeros raised net proceeds of $54.5 million in a December 2019 secondary, which should leave it with ~$70 million at YE19. It has convertible debt with a face value of $210 million ($155 million carrying value) due 2023. The company also has an untapped vehicle through which it can borrow 85% of its receivables up to $50 million. Its cash runway will be contingent on securing separate payment status for Omidria post-September 2020 and the cadence of its development programs.

Like the investment community, Street analysts are somewhat split on Omeros prospects with one outperform rating sandwiched in between two buys and two holds. Their median twelve-month price target, however, is around $25 a share.

There are some unknowns regarding Omeros. Besides Omidrias status, the timing surrounding the completion of two of its pivotal OMS721 trials is still unclear in one instance, after three years. What does seem clear is that the FDA wants to approve OMS721. Given the lack of approved remedies for these complement systems diseases, OMS721 has relatively low hurdles to jump. If eventually approved for all three indications, OMS721 has blockbuster potential. If Omidria obtains five years of separate payment status, it will pave the way for Omeros to finance its own R&D without any more trips to the capital markets. With many shots on goal and what appears to be a helping hand from the FDA, continued investment in the shares of OMER is merited.

Idealism is fine, but as it approaches reality, the costs become prohibitive. William F. Buckley

Bret Jensen is the Founder of and authors articles for the Biotech Forum, Busted IPO Forum, and Insiders Forum

The Biotech Forum sports one of the liveliest collections of seasoned biotech investors on Seeking Alpha along with a 20-stock model portfolio. Join us during every trading day on Live Chat where the community swaps trading ideas, breaking news and opinions around all things Biotech. Initiate your risk-free, two week trial into The Biotech Forum by clicking HERE.

Disclosure: I am/we are long ALXN,OMER. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more here:
Omeros: 2 Major Catalysts On The Horizon - Seeking Alpha

PRACTICALLY ACTIVE: Screening is a smart way to start a healthier life – NWAOnline

I've been endeavoring to eat healthfully these days, but sometimes it seems like an uphill battle. I'm eating fewer carbohydrates and have noticed an improvement in my blood glucose levels. But there are those times i check "my sugars," and when they are too high, I can usually trace it back to something i ate.

I try not to eat too late at night, and if I do, I try to go for something that offers a good amount of protein. But there are other times that I get into something I shouldn't. Thankfully, after all these years, I've finally let it sink in that beating myself up for that does not help. I'm too old to deprive myself and old enough to know I need to do better for my health, my family and my future.

I had a physical a few years ago from stem to stern. I had a mammogram as well and got a pretty good report, considering I'm diabetic. I've worked to clean up my cholesterol. I do have blood pressure concerns, but at least I know about it and can work to improve my situation.

Insurance is expensive and out-of-pocket costs can stop us cold. How many people just endure health problems because they don't have the funds or insurance coverage? How many people have high insurance premiums and high deductibles to the point that their policy is basically something to have in case of a catastrophic event? Millions.

If you can't afford a full physical, there are options. It takes some investigative work and diligence, but there are clinics and nonprofit hospitals that could help.

While watching TV the other day, I saw a commercial for free health screenings courtesy of the Arkansas Minority Health Commission (arminorityhealth.com). It's part of the Arkansas Department of Health. They screen for blood pressure, body mass index and blood glucose. Screening is a good place to start to get a grip on your health.

The screenings, which are open to everyone, are offered on the first Wednesday of every month from 10 a.m. to 2 p.m. at 1501 S. Main St., Suite A, Little Rock. For information, call (501) 686-2720.

I always wished I was a person who loved to exercise. As children, my sisters and I played outside for hours on end. But that was playing, I wanted to do it. These days I don't want to exercise, and I don't enjoy it. Some days I'm worn out by the time I get home. But I'm trying to let it sink in that for my health and well-being, I need to stop being so sedentary.

I know how important health care, exercise and healthful eating are to longevity. But it takes effort, and I have to really work on my motivation.

One aspect of health that I often don't consider is mental, especially in regard to aging. While diseases like Parkinson's or Alzheimer's might affect us regardless of our physical health, there are other problems that could beset us because we get stagnant and, dare I say it, lazy.

I ran across an article on the Mayo Clinic website about the association between cardiorespiratory fitness and brain health, particularly in gray matter and total brain volume, loss of which is involved in cognitive decline and aging.

Brain tissue is made up of gray matter, or nerve cell bodies, and nerve filaments, called white matter, that extend from the cells. It was found that increases in peak oxygen uptake were strongly associated with more gray matter volume.

According to Dr. Ronald Petersen, a Mayo Clinic neurologist, there is indirect evidence that regular aerobic exercise can have a positive impact on cognitive function, in addition to physical conditioning.

Cardiorespiratory fitness is a measure of how well your body is able to transport oxygen to your muscles during prolonged exercise, and how your muscles are able to absorb and use oxygen.

The experts recommend moderate and regular exercise about 150 minutes a week. The recommended exercises include things like running/jogging, swimming, cycling, aerobics and jumping rope. Choose an exercise that involves fast movements for an extended period of time. You can choose a variety of types to keep your training routine from growing stale.

Now, I'm on to finding workouts to suit my mobility limits. I've had results from chair workouts that include weight-bearing exercises too. I'll share what I find with you.

Email me at:

rboggs@adgnewsroom.com

Style on 02/10/2020

Read more from the original source:
PRACTICALLY ACTIVE: Screening is a smart way to start a healthier life - NWAOnline

Arthritis treatment: A controversial treatment promoted by a certain royal could help – Express

Arthritis is an umbrella term for a number of conditions that cause swelling and tenderness of one or more of the joints. Osteoarthritis and rheumatoid arthritis are the two most common types of arthritis. There's no cure for arthritis, but there are many treatments that can help slow it down and maintain quality of life, including this unusual one.

Osteoarthritis mainly affects the hands, spine, knees and hips, whereas rheumatoid arthritis usually affects the hands, feet and wrists.

Experts are researching ways to use stem cells therapy to help treat arthritis in the knee and other joints.

Many doctors already use stem cell therapy to treat arthritis, but it is not considered standard practice, with some even calling the treatment controversial.

READ MORE: Joe Swash health: I had to learn everything again Actors scary virus

There is a lot of debate around stem cell treatment and it is helpful for potential patients to understand what stem cells are and the issues surrounding their use in arthritis therapy.

How the treatment could help is by reducing inflammation in the body.

In arthritis, the immune system mistakenly attacks the tissue that lines the joints, which causes pain, inflammation, swelling and stiffness.

By reducing inflammation, stem cell therapy increases the presence of healthy cells in the body.

DONT MISS

And it would seem that stem cell therapy has sparked some interest from the royal family.

Princess Michael of Kent, the wife of the Queens cousin Prince Michael, recently appeared in a slick promotional video for a clinic in the Bahamas that offers similar joint therapy.

Look at that, the Princess declares proudly in the five-minute film, holding her right arm high above her head after stem-cell injections for a painful shoulder.

"Its amazing I think stem cells are the future, theres no doubt in my mind."

A stem cell is a type of cell not specialised to perform a specific role.

Instead, it has the unique ability to develop into one of many different types of cell. Stem cell therapy uses stem cells to replace dead and diseased cells within the body.

The human body contains over 200 different types of cell. Usually, each type has certain characteristics that allow it to preform a specific role.

Cells with similar roles group together to form tissues, which then organise to form the bodys organs.

Scientists source the stem cells from body tissue, either from an embryo or an adult human and isolate them in the laboratory.

After manipulating the cells to develop into specific types, they then inject the cells into the recipients blood or tissue.

Researchers are still investigating ways of using stem cells to control inflammation and regenerate damaged tissues.

Mesenchymal stem cells (MSCs) are types of stem cell that can develop into cartilage and bone. Synovial MSC therapy involves injecting these cells directly int the tissues surrounding the affected joints.

Some research shows that MSCs are also able to suppress the immune system and reduce the bodys inflammatory response.

This makes MSC therapy a promising treatment option for autoimmune conditions such as arthritis.

But for all the positive evidence supporting the treatment, it remains hugely controversial.

Most specialists say there is little robust evidence to show it works and it has not been approved by the UK medicines regulator, the National Institute for Health and Care Excellence. Leading health experts most standard approaches to treating arthritis is advising patients to lose weight and get more exercise.

In the US, Google has banned all advertising for products that contain stem cells or another regenerative therapy which uses blood cells, known as platelet-rich plasma, or PRP, because regulators describe the treatments as "new and exploratory".

And in the UK, experts have rubbished claims that Lipogems can treat arthritis.

Professor Chinmay Gupte, consultant orthopaedic surgeon and senior lecturer in knee surgery at Imperial College London, warns: These are extremely expensive treatments, and largely unproven. The problem is when youre desperate, youll try anything.

Read the original here:
Arthritis treatment: A controversial treatment promoted by a certain royal could help - Express

Research could be step toward lab-grown eggs and sperm to treat… – ScienceBlog.com

A new study on how and when the precursors to eggs and sperm are formed during development could help pave the way for generating egg and sperm cells in the lab to treat infertility.

The study, publishedin the journal Cell Reports, describes the way in which human stem cells evolve into germ cells, the precursors for egg and sperm cells.

Right now, if your body doesnt make germ cells then theres no option for having a child thats biologically related to you, said Amander Clark, the studys lead author, a member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. What we want to do is use stem cells to be able to generate germ cells outside the human body so that this kind of infertility can be overcome.

It is estimated that infertility affects 10% of the U.S. population, and infertility rates have increased over the past several decades because more people are waiting longer to have children. Many forms of infertility can be treated using procedures that join egg and sperm together outside the body, such as in vitro fertilization and intracytoplasmic sperm injection. But for people whose bodies dont produce eggs or sperm because of chemotherapy, radiation, genetics or other unexplained causes those treatments arent an option unless a donor provides the eggs or sperm.

With donated eggs and sperm, the child is not genetically related to one or both parents, said Clark, who also is a UCLA professor and chair of molecular cell and developmental biology. To treat patients who want a child who is genetically related, we need to understand how to make germ cells from stem cells, and then how to coax those germ cells into eggs or sperm.

In developing male and female embryos, a subset of pluripotent stem cells cells that have the potential to become nearly every type of cell in the body become germ cells that will later generate eggs or sperm. Researchers previously demonstrated the ability to make similar stem cells in a laboratory, called induced pluripotent stem cells, or iPS cells, from a persons own skin or blood cells.

Clark and her colleagues used technology that enables them to measure the active genes in more than 100,000 embryonic stem cells and iPS cells as they generated germ cells. Collaborators at the Massachusetts Institute of Technology developed new algorithms to analyze the massive amounts of data.

The experiments revealed a detailed timeline for when germ cells form: They first become distinct from other cells of the body between 24 and 48 hours after stem cells start differentiating into cell types that will ultimately make up all the specialized cells in the adult body.

Clark said that information would help scientists focus their efforts on that particular timeframe in future studies, in order to maximize the number of germ cells they can create.

The study also revealed that the germ cells come from two different populations of stem cells amnion cells, which are located in the fluid and membrane that surrounds the embryo during pregnancy, as well as gastrulating cells from the embryo itself.

When the researchers compared the germ cells derived from embryonic stem cells with those derived from iPS cells in the lab, they found that the patterns by which genes were activated were nearly identical.

This tells us that the approach were using to begin the process of making germ cells is on the right track, Clark said. Now were poised to take the next step of combining these cells with ovary or testis cells.

That next step is critical because molecular signals from ovary or testis tissue are what signal germ cells to mature into eggs and sperm.

If the approach were to be incorporated into a future treatment for infertility, scientists might eventually be able to use a patients own skin cells to form stem cells that can be coaxed into both germ cells and ovarian or testis tissue and those cell types might be able to be used to generate a persons own eggs or sperm in the lab.

Were going in the right direction but it will take a lot of new innovations to solve infertility related to the loss of germ cells, Clark said.

The techniques described above were used in laboratory tests only and have not been tested in humans or approved by the Food and Drug Administration as safe and effective for use in humans.

The research was supported by the National Institutes of Health and a Broad Stem Cell Research Center Innovation Award.

Media Contact

Mirabai Vogt-James310-983-1163mvogt@mednet.ucla.edu

Continue reading here:
Research could be step toward lab-grown eggs and sperm to treat... - ScienceBlog.com

First dual stem cell therapy jointly developed by City University of Hong Kong brings new hope for cardiac repair – QS WOW News

A research team featuring an expert from City University of Hong Kong (CityU) has developed a novel dual approach for the first time for concurrently rejuvenating both the cardiac muscle and vasculature of the heart by utilising two types of stem cells. The results give hope for a new treatment for repairing myocardial infarction (MI) heart.

Dr Ban Ki-won, Assistant Professor of the Department of Biomedical Sciences and his research team, including researchers from Konkuk University, The Catholic University of Korea, Pohang University of Science and Technology and T&R Biofab in South Korea, have conducted the first study of two distinct stem cell effects for cardiac repair. The two major types of stem cells employed are human bone marrow derived mesenchymal stem cells (hMSCs) and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). The research findings have been published in Nature Communications in a paper titled Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction.

Both cardiac muscles and vasculatures are severely damaged following MI, and so the therapeutic strategies should focus on comprehensive repair of both at the same time. But the current strategies only focus on either one, Dr Ban said.

Dr Ban said that, with limited therapeutic options for severe MI and advanced heart failure, a heart transplant was the last resort. However, such an operation is very risky, costly and subject to limited supply of suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

In the study, the hiPSC-CMs were injected directly into the border zone of the rats heart, while the hMSCs-loaded patch was implanted on top of the infarct area, like a bandage. The results showed that this dual approach led to a significant improvement of cardiac function and an enhancement of vessel formation on a MI heart.

We believe this novel dual approach can potentially provide translational and clinical benefit to the field of cardiac regeneration. Based on the same principle, the protocol may also be utilised for repairing other organs including the brain, liver and pancreas in which multiple types of stem cells co-exist, Dr Ban added.

The research team is working on follow-up studies in larger animal models such as pigs. The patent application for this research result has been submitted.

See the original post here:
First dual stem cell therapy jointly developed by City University of Hong Kong brings new hope for cardiac repair - QS WOW News

Chromatin accessibility analysis reveals regulatory dynamics of developing human retina and hiPSC-derived retinal organoids – Science Advances

INTRODUCTION

The process of vision starts from the retina, a part of the central nervous system (CNS) that processes both image- and nonimage-forming visual information (1, 2). The retina, composed of multiple types of neurons (photoreceptors, horizontal cells, bipolar cells, amacrine cells, and retinal ganglion cells) and a single type of glial cells (Mller cells) differentiated from retinal progenitor cells (RPCs), is an excellent system for studying the regulation of neurogenesis in the CNS (3, 4). Tremendous progress has been made in deciphering the complex molecular mechanisms underlying retinal neurogenesis in rodents (57). In contrast, knowledge regarding the molecular mechanisms underlying human retinogenesis remains scarce. Recent advances in human retinal studies provide valuable gene expression and epigenetic profiles of the developing human retina (8, 9). However, the transcriptional regulatory network, which can provide insight into the regulation of interactional transcription factors (TFs), remains poorly understood during human retinal development. The assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) has emerged as a sensitive and robust method for open chromatin assays, nucleosome site mapping, and TF occupancy analysis (10, 11). Moreover, ATAC-seq is also applicable for establishing the transcriptional regulatory network during development, as integration of known TF motifs with chromatin accessibility data from ATAC-seq can predict a genome-wide regulatory network (10). Therefore, systematic ATAC-seq analysis will be a powerful tool to decipher the epigenetic features and transcriptional regulatory network during human retinal development.

Studies on the underlying regulatory mechanisms of human retinal development have been hampered by the impossibility of direct molecular and genetic manipulation of human retinae in vivo. Retinal organoids (ROs) derived from human induced pluripotent stem cells (hiPSCs) are three-dimensional retinal-like structures grown in vitro, which contain the main cell types and proper apical-basal polarity of retinae (12). Thus, ROs provide an opportunity to study human retinal development and disorders with additional flexibility for molecular and genetic manipulations. Previous studies have applied ROs to mimic disease processes and cell transplantation for retinal regeneration (1315). However, advances in clinical studies using ROs have been hindered by our limited understanding of the molecular and functional differences between the developing human retina and ROs. Furthermore, it is unclear to what extent ROs recapitulate the development of the human retinae in epigenetic modifications. Therefore, it is critical to establish the epigenetic correlations between the developing human retina and ROs.

The dynamics of chromatin accessibility play an important role in regulating human development, including cell fate determination, cell differentiation, and diseases occurrence (16, 17). Recent studies have shown that rod and cone photoreceptors display distinct chromatin accessibility landscapes during fate determination in mice, suggesting that cellular epigenomic states are crucial for retinal neurogenesis (18). In this study, using ATAC-seq and RNA sequencing (RNA-seq) analysis, we explored the chromatin accessibility and transcriptional changes in human retinae and ROs over long-term retinal development. Our results showed that the developing human retina exhibited a complex pattern of chromatin dynamics accompanying retinogenesis. Further analysis indicated that ROs recapitulated the human retinogenesis to a great extent, but divergent epigenetic signatures were found. Moreover, we identified two TFs [nuclear factor I B (NFIB) and thyroid hormone receptor alpha (THRA)] as essential regulators in human retinal development and validated their functions via gene manipulation in ROs. The transcriptional regulatory networks were reconstructed in human and RO, and signaling pathways were analyzed in human and murine retinal development, providing an invaluable data source for future molecular mechanism studies. The chromatin modifications during human and murine retinal development were cross-analyzed and revealed that a bivalent domain of H3K4me3 and H3K27me3 modifications enriched in human only, suggesting a unique and more dedicated epigenetic regulation on human genome. Together, our systematic profiling and integrative analyses of epigenetic and transcriptional changes provide a comprehensive view of the chromatin landscapes that accompany the murine, human retinal, and RO development; establish a developmental temporal-correlation roadmap between the human retinae and ROs; and present a data source for modifying RO culture under the guidance of in vivo human retinal development.

To determine the chromatin accessibility in developing human retina and ROs, the developing human retina from gestational week 6 (GW6) to GW25 at nine time points (GW6, GW10, GW11, GW12, GW14, GW15, GW20, GW24, and GW25; two biological replicates at GW11, GW15, GW20, GW24, and GW25; n = 1 at GW6, GW10, GW12, and GW14), which spanned the key human retinal developmental stages (8), and hiPSC-derived ROs from week 0 to week 30 (w0, w2, w4, w6, w10, w15, w23, and w30; two biological replicates at all stages) were collected for ATAC-seq analysis (Fig. 1A). Each ATAC-seq library was sequenced to obtain, on average, more than 50 million total raw reads per sample. ROs were differentiated as per previous protocols (15). We also conducted RNA-seq for w0, w2, w6, w10, w15, and w23 ROs (n = 1 at all stages). RNA-seq data of the developing human retina were obtained from previous study (8). Here, we stained the developmentally regulated gene RECOVERIN (RCVRN) and nuclear receptor subfamily 2 group E member 3 (NR2E3) in developing human retina and ROs as indicators of differentiation from RPCs to photoreceptors (Fig. 1, B and C, and fig. S1, D and E). Our data revealed that RCVRN protein expression emerged at GW14 and w10 in the human retinae and ROs, respectively, with the expression sustained to GW25 and w30. Like RCVRN, the rod photoreceptor marker NR2E3 was shown at GW20 and w15, respectively. These similar expression trends of the photoreceptor markers indicated that RO culture exhibited progressive retinal neurogenesis, as found in the human retinae.

(A) Schematic illustration of the overall experimental designs. Whole human neural retinae and ROs were collected for ATAC-seq (two replicates labeled with asterisk) and RNA-seq (inverted triangle). Development of human retinae and ROs was grouped into early, middle, and late stages and color coded. Immunostaining of GNAT1 in human retinae GW25 and ROs w30 is shown. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). Undiff, undifferentiated; Early, early developmental stage; Mid, middle developmental stage; Late, late developmental stage. Scale bars, 500 m (bright-field images) and 10 m (fluorescence images). PC1, principal component 1; PC2, principal component 2. (B and C) Immunostaining of RCVRN in human retinae (B) and ROs (C). Nuclei were stained with DAPI. NBL, neuroblastic layer; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer. Scale bars, 20 m. (D) Heat map of Pearson correlations across all samples using all ATAC-seq peak signals. Relevant developmental stages are labeled with distinct colors as in (A). (E) PCA of chromatin accessibility during human retinal (blue) and RO (red) development in two dimensions. The black dotted arrow indicates the development process of retinogenesis. (F and G) Normalized epigenetic and expression profiles at the RCVRN loci during human retinal development (F) and RO differentiation (G). All signals were obtained from the University of California, Santa Cruz (UCSC) genome browser. (H) qRT-PCR analysis of the expression level of RCVRN (n = 3) during RO differentiation. Data are means SEM. One-way analysis of variance (ANOVA) was performed. ****P < 0.0001.

The ATAC-seq data were analyzed using the ATAC-pipe (19) to obtain the chromatin accessible sites in the developing human retina and RO. Transcription starting site (TSS) enrichment from all samples, aligned fragment length distribution of all samples, and correlation analysis of all the replicate samples indicated high-quality data and excellent reproducibility between replicates (fig. S1, A to C). We also performed correlation analysis of the ATAC-seq peak intensities to define the similarities in chromatin accessibility between the human retinae and ROs (Fig. 1D). The sample replicates were strongly clustered with each other, confirming the high reproducibility of the experiments. Here, except w0 (the undifferentiated hiPSCs), the entire retinal development process can be grouped into three time periods, that is, the early (GW6; w2 to w6), middle (GW10 to GW14; w10 to w15), and late (GW15 to GW25; w23 to w30) stages (color coded in Fig. 1, A and D, and fig. S1F), indicating that human retinae and ROs were developmentally correlated in chromatin accessibility. In addition, the ATAC-seq peaks were also clustered with deoxyribonuclease I (DNase I) hypersensitive site sequencing (DHS-seq) data in day 74 (D74) (DHS-GW11) and D125 (DHS-GW18) retinae produced by the encyclopedia of DNA elements (ENCODE, http://www.encodeproject.org/) project (Fig. 1D). Principal components analysis (PCA) revealed that the development trajectories of the human retinae and ROs were temporally related in two dimensions. Similar results were found by uniform manifold approximation and projection (UMAP) analysis (Fig. 1E and fig. S1F). Together, these findings suggested the developmental relevance between human retinae and ROs. However, note that although ROs and human retinae were clustered together in the middle stage, the two groups were split apart (fig. S1F, light yellow coded with white dot line), suggesting that the epigenetic signatures might be slightly different between human retinae and ROs at this stage.

We next investigated whether chromatin accessibility was related to gene expression changes. As a positive control, we found elevated enrichment of the ATAC-seq and DHS-seq signals at putative promoters and enhancers at the RCVRN gene locus, consistent with the stages when the gene was expressed (Fig. 1, F and G). Moreover, quantitative real-time polymerase chain reaction (qRT-PCR) quantified the expression level of RCVRN in ROs during the differentiation process (Fig. 1H), confirming consistency between the enrichment of RCVRN expression and chromatin dynamics obtained from the ATAC-seq data. In addition, NR2E3 also showed consistency in chromatin accessibility and gene expression dynamics during human retinal and RO development (fig. S1, G and H). Collectively, our data suggested that RO differentiation recapitulated human retinal development to a great extent. On the basis of the chromatin accessibility profile of developing human retina and ROs, we established the maps of the temporal correlation between the human retinae and ROs.

To delineate how epigenomic dynamics governs human retinal development, we applied pairwise comparisons of the ATAC-seq signals of human retinae and ROs at different developmental time points. We discovered 10,563 differential DNA accessible sites across the genome (8805 elements from human retinae and 10,160 elements from ROs) and identified five distinct regulatory element clusters (C1 to C5) via unsupervised hierarchical clustering (Fig. 2A). To understand the functions of these notable differential peaks, we applied Gene Ontology (GO) term enrichment analysis using GREAT v3.0.0 (20). GO analysis of the C1 to C5 cluster peaks revealed three main functional groups for the differential accessible sites: The first functional group included C1 and C2, which were composed of 1636 and 2759 elements, respectively. These peaks were highly accessible in the beginning (GW6 and w0 to w6) but progressively declined with human retinal and RO development. GO analysis identified that these peaks were associated with early retinal development, such as neural tube formation (P < 1 105), neural tube closure (P < 1 105), regulation of neuron differentiation (P < 1 107), and neural precursor cell proliferation (P < 1 106) (fig. S2, A and B). Because C3 consisted of only 478 peaks and showed no enriched GO terms, peaks in C3 were not further analyzed. The second major functional group was C4, which was composed of 3065 peaks. These C4 peaks were accessible from the middle developmental stage (GW10) and sustained to the late stage (GW25) in the human retinae. Strikingly, the C4 peaks were accessible only in the late RO developmental stage (w23 to w30). GO analysis revealed that the peaks in C4 were strongly enriched in nervous system development, including neurogenesis (P < 1 1060) and neuron differentiation (P < 1 1042) (Fig. 2B), suggesting their key roles in retinal neurogenesis. The third functional group was C5, which included peaks that were not accessible in the beginning but were gradually established during the late developmental stage of both human retinae and ROs (GW15 to GW25 and w10 to w30). The C5 group included 2624 peaks enriched in sensory perception of light stimulus (P < 1 108), visual perception (P < 1 107), and photoreceptor cell differentiation (P < 1 106), which represented the functional maturation of the human retinae, especially the photoreceptors (Fig. 2C). Thus, the GO terms from these three functional groups represented the sequential retinogenesis in human retinae, and the classification of chromatin accessibility provided the possibility to define the timing of key developmental events during human retinal and RO development. From the chromatin accessibility data, we observed that in vitro RO differentiation recapitulated the in vivo human retinal development to a great extent. However, note that the peaks in C4 opened later in RO differentiation than those in human retinal development. It is likely that the distinct pattern of C4 provided possible clues to direct RO differentiation closer to human retinae by genetic manipulation of the regulators related to the C4 peaks.

(A) Heat map of 10,563 differential regulatory elements during human retinal and RO development. Each column is a sample, and each row is a peak. Color scale shows the relative ATAC-seq peak intensity centered at the summit of each peak. Distance of cluster peaks to their nearest gene promoters is shown on the right. (B and C) Significant GO terms enriched in C4 (B) and C5 (C) cluster peaks using GREAT v3.0.0. The number of genes enriched in GO terms is shown in the parentheses. (D) Comparison of open-ended DTW analysis between human retinae and ROs. There were 3235 DEGs in humans. Gene expression data were subjected to open-ended DTW analysis, with results plotted as a heat map. (E to H) Violin plot representing the expression level of genes closest to the top 1000 peaks in C1 (E), C2 (F), C4 (G), and C5 (H) during human retinal development showing a variable but positive correlation between chromatin accessibility and gene expression. GREAT was used to annotate peaks to genes. Statistical significance was analyzed with one-way ANOVA. ***P < 0.001, ****P < 0.0001.

We also performed pairwise comparisons of RNA-seq analysis of developing human retina and ROs (fig. S2C). We identified distinct G1 to G4 clusters in the RNA-seq data. Genes in the G1 cluster were associated with early developmental processes, such as cell division, DNA replication, and mitotic cell cycle. G2 genes were associated with axon guidance and regulation of neuron projection development. Genes in G3 were related to visual perception and phototransduction. G4 genes exhibited nonspecific biological processes with retinal development; thus, G4 was not used for further analysis. Therefore, the GO terms (G1 to G3) of RNA-seq data revealed similar sequential retinal development between human retinae and ROs. To further compare the human retinal and RO transcriptome during retinal development, we performed open-ended dynamic time-warping (OE-DTW) analysis (21) of 3235 differentially expressed genes (DEGs) from human retinae (Fig. 2D). We observed a tight temporal correlation between human retinae (GW7 to GW20) and ROs (w0 to w23), confirming that human retinae and ROs shared considerable similarities in gene expression changes. We next examined whether the chromatin signatures in different clusters (C1 to C5) were correlated with the corresponding gene expressions. We chose the top 1000 peaks in each cluster and then applied GREAT to obtain a list of genes regulated by the ATAC-seq peaks and correlated their expression values. By combining the ATAC-seq profiles with the RNA-seq data during retinal development, genes near the loci that gained chromatin accessibility showed significant increases in gene expression levels, whereas genes near the loci that lost chromatin accessibility exhibited decreased expression (Fig. 2, E to H, and fig. S2, D to G), indicating a high correlation between epigenetic and RNA profiling. The correlation between epigenetic and RNA profiling was further analyzed on cell lineage markers, such as PAX6 (retinal progenitor marker), GNAT1 (rod marker), GNGT2 (cone marker), GLUL (Mller cell marker), PROX1 (horizontal cell marker), TFAP2A (amacrine cell marker), and VSX1 (bipolar cell marker) (fig. S3, A to G). Most of the markers showed the similar trends in chromatin accessibility and gene expression during retinal development, suggesting that the chromatin accessibility may govern the gene expression. Together, we observed sequential chromatin changes associated with retinogenesis and correlated with gene transcription; thus, the developmental transitions during retinogenesis can be reflected in the epigenome dynamics.

To identify potential TFs involved in human retinal development, we searched for TFs enriched at accessible sites in C1, C2, C4, and C5 using HOMER v4.8. As accessible DNA sites are often obligated if TFs bind to their cognate DNA motifs, the integration of TF motifs and DNA accessibility data from ATAC-seq can predict TF occupancy on chromatin and thus create regulatory networks (16, 17, 22, 23). Our data revealed distinct patterns of TFs in different clusters. The TFs enriched in the C1 and C2 peaks were identified as potential regulators of early retinal development (fig. S4, A and B). For example, PAX6 is a key regulator for maintaining the multipotency of RPCs (24). SOX3 and RUNX are well known for self-renewal maintenance and morphogenesis (25, 26).

The TFs enriched from C4 and C5 ATAC-seq peaks were identified as critical regulators for neuronal and photoreceptor differentiation, respectively (Fig. 3, A and B). For instance, cluster C4 was enriched with VSX2, SMAD2, and NEUROD1, which are important for retinal neurogenesis (2729). C5 was enriched with OTX2, CRX, and NR2E3, which are key regulators of photoreceptor differentiation. OTX2 is required for RPC differentiation and cell fate determination (30, 31). CRX is a key regulator for the survival and differentiation of photoreceptors (32). NR2E3 is a direct target of NRL involved in rod and cone photoreceptor differentiation in rodents (33). Therefore, the TFs predicted from the ATAC-seq data were highly associated with retinogenesis and differentiation.

(A and B) TF motifs enriched in C4 (A) and C5 (B) peaks, with P values estimated from HOMER v4.8. (C) Predictions of TFs that may regulate human retinal development (left) and RO differentiation (right). TFs known to be involved in regulating retinal development are shown on top (red). The color of each circle represents expression level of genes that encode corresponding TFs, and the size of the circle represents the enrichment of the motifs. Relevant developmental stages are labeled with distinct colors as in Fig. 1A. (D) Visualization of ATAC-seq footprint for motifs of ASCL1, CRX, NFIB, and THRA in four developmental stages of human retinae. ATAC-seq signals across all motif binding sites in the C4 and C5 genome regions were aligned on the motifs and averaged.

Since C4 and C5 peaks were associated with the middle and late stages of retinal development, which were important for neurogenesis and phototransduction, we focused on C4 and C5 to search for previously unknown neurogenesis regulators. One caveat of only using motif analysis for TF prediction is that TFs or TF families can share the same motif; therefore, we integrated motif enrichment analysis by ATAC-seq data and gene expression profiles from the RNA-seq data to better predict the TF occupancy on accessible sites of C4 and C5. At each time point, we plotted the expression value and motif enrichment score on the same figure (Fig. 3C), which showed that many well-known photoreceptor development TFs were highly expressed, and their motifs were enriched at the middle and late stages (GW10 to GW20 and w10 to w23), including CRX, OTX2, ASCL1, and NR2E1. We found TFs NFIB and THRA, which showed similar high expression and motif enrichment at the middle and late retinal developmental stages. NFIB and THRA have not been reported in photoreceptor differentiation. Therefore, to evaluate their involvement in retinal development, we studied all differentially expressed downstream genes containing the binding motifs of NFIB and THRA together with two well-known retinal development regulators (ASCL1 and CRX) as the control (fig. S4C). GO analysis indicated that up-regulated downstream targets of all four factors were involved in retinal development, including visual perception and phototransduction. Thus, NFIB and THRA may participate in the regulation of retinal development.

To further refine our prediction of the potential regulators of retinal development, TF footprint analysis of the ATAC-seq data, which provides evidence of direct occupancy of TF candidates on genomic DNA, was performed. DNA sequences directly occupied by DNA binding proteins are protected from transposition during library construction in ATAC-seq, and therefore, the resulting sequence footprint reveals the presence of a DNA binding protein at its binding sites, analogous to DNase digestion footprints. We illustrated the footprints of two known regulators, ASCL1 and CRX, and observed deeper footprints and higher DNA accessibility flanking their motifs in the late stage compared with the early stage of human retinal and RO development (Fig. 3D and fig. S4D). Notably, the footprints of NFIB and THRA were also deeper and more accessible at the late stage, suggesting that the motifs of these two TFs were not only enriched at stage-specific peaks but also most likely physically bonded to the chromatin accessible sites, indicating that they were possible functional regulators of human retinal and RO development. Collectively, the orthogonal footprint results were consistent with the motif enrichment results, indicating that NFIB and THRA were potential previously unidentified regulators of retinal development.

As ROs were similar to human retinae in gene expression and chromatin accessibility, we used ROs as a model to investigate the potential role of NFIB and THRA during retinal development. We established an electroporation method to efficiently overexpress or knock down target genes in ROs. The outer regions of bright neuroretinal epithelium in ROs were cut into ~500-m (diameter) pieces and placed into cuvettes for electroporation (Fig. 4A). Electroporated RO samples were collected for qRT-PCR or RNA-seq analysis on D10 after electroporation (Fig. 4B). We investigated the function of three genes, CRX, NFIB, and THRA, in retinal development. As a positive control and to test our electroporation system, CRX was knocked down in ROs around w14 and overexpressed around w7. The qRT-PCR results indicated that CRX knockdown (CRX_KD) reduced the expressions of NRL and RAX2, which were targets of CRX related to photoreceptor differentiation (fig. S5A). Conversely, overexpression of CRX (CRX_OE) markedly elevated the expressions of NRL, ARR3, and OPN1SW (fig. S5, B and C). Both CRX_KD and CRX_OE experiments suggested that our system can successfully manipulate gene expression in RO for studying retinal development. GO analysis of down- and up-regulated DEGs of CRX_OE samples suggested that CRX is involved in visual perception (fig. S5, D and E). Thus, these results indicated that we established a reliable gene manipulation system in ROs. Next, specific short hairpin RNA (shRNA) vectors for NFIB or THRA knockdown were electroporated into ROs at ~w14, a time point when NFIB and THRA were expressed. We revealed significantly decreased expression of NFIB and THRA by qRT-PCR or RNA-seq analysis (Fig. 4C and fig. S5, F and G), respectively. To validate the functional knockdown of these two TFs, we next analyzed the expression level of EZH2, a known target of NFIB, and ARNTL, a potential target of THRA. Results revealed that the expressions of EZH2 and ARNTL decreased significantly due to loss of NFIB and THRA, respectively (Fig. 4C and fig. S5G). Notably, we found that a set of photoreceptor-associated genes were down-regulated, including CRX, RHO, and GNAT1, under knockdown of NFIB and THRA, suggesting that NFIB and THRA may be involved in regulating photoreceptor differentiation (Fig. 4, C and D, and fig. S5G). NFIB is highly expressed in fetal cerebral cortex neural progenitor and glial cells and is required for neuronal and glial differentiation in the fetal cerebral cortex (34). Considering that neurogenesis regulation in the CNS is conserved, we selected NFIB for further functional studies. The RNA-seq of NFIB knockdown (NFIB_KD) ROs revealed many down-regulated retinogenesis genes, including GNAT1, NR2E3, and GNGT2 (Fig. 4D). GO analysis of down- and up-regulated genes in NFIB_KD RNA-seq strongly suggested that NFIB was required for retinal development, especially for photoreceptor differentiation (Fig. 4, E and F). In addition, we further used immunohistochemistry to detect the NFIB_KD effect on highly expressed photoreceptor-related protein, RCVRN, between w14 and w15 (Fig. 4G). The quantification results of the relative intensity of RCVRN implied that NFIB_KD reduced the protein expression of RCVRN (Fig. 4H). Similarly, the percentage of RCVRN-positive cells also reduced accordingly in NFIB_KD ROs (Fig. 4I). Together, these data demonstrated that NFIB and THRA were involved in human retinal and RO development. It is possible that NFIB and THRA affected the self-renewal and differentiation ability of RPC to photoreceptors and Mller cells. However, the hypothesis needs to be further investigated.

(A) Schematic illustration of ROs split into small sheets for electroporation. Dotted line represents clipping path. (B) Representative images of RO sheets transfected with reported plasmids 10 days after electroporation. Scale bar, 500 m. (C) qRT-PCR analysis of expression levels of genes after knockdown of NFIB (n = 5). Data are means SEM. (D) Plot representing DEGs between control and NFIB_KD groups. Significantly up- and down-regulated genes (fold change >1.5) are highlighted in red and blue, respectively. (E and F) Significant GO terms enriched in down- (E) and (F) up-regulated genes, respectively, in the NFIB_KD experiment. The number of genes enriched in GO terms is shown in the parentheses. (G) Immunostaining of RCVRN in NFIB_KD ROs and control ROs, respectively. Scale bars, 20 m. (H) Relative intensity of RCVRN signals in the control (n = 366 cells from five independent ROs) and NFIB_KD (n = 135 cells from four independent ROs) groups. (I) Percentage of RCVRN-positive cells in the control (n = 5 independent ROs) and NFIB_KD (n = 4 independent ROs) groups. All statistics by two-tailed Students t test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

To further understand the molecular mechanism underlying NFIB-regulated retinal development, we analyzed the potential NFIB-regulated pathways and related functions by ingenuity pathway analysis (IPA) via comparing the gene expression between NFIB_KD ROs and their control (fig. S6A). The results revealed that phototransduction-associated pathways/functions were enriched in down-regulation genes, further confirming the regulation of NFIB of photoreceptors. Moreover, we examined the potential binding of NFIB to retinal developmentrelated genes. We selected the genes enriched in the highlighted pathways in fig. S6A. We then searched for the binding sites of NFIB in the peak region around these genes. To better determine the possibility of these genes bonded by NFIB motifs, we then define their binding affinities using their signals of footprint flank divided by footprint depth signaling (fig. S6B). The results showed that PROM1 and NR2E3 had high affinity with NFIB motifs. NFIB motifs occupying the gene PROM1 and NR2E3 loci also showed opening chromatin states (fig. S6, C and D); therefore, PROM1 and NR2E3 were potential target genes of NFIB. Overall, NFIB is highly possibly involved in retinal development by regulating photoreceptor-related targets.

TFs often work in a network by cross-talking with each other to regulate gene transcriptions. To establish the potential connection of enriched TFs, we reconstructed a global picture of the TF regulatory networks during human retinal and RO development. First, we used HOMER v4.8 to identify the enriched TFs bound to the C1 to C5 peaks (P < 1 1020). The connections (edges) between TFs were defined as follows: If TF-Xs motif were on the promoter of TF-Y, then TF-X regulated TF-Y, thereby drawing an arrow from TF-X to TF-Y. Here, only TFs distinctly expressed at this time point were considered. On the basis of this rule, we constructed the transcriptional regulatory networks of human retinae (GW6, GW10, and GW20) and ROs (w6, w10, and w23) at the early, middle, and late stages, respectively (Fig. 5, A and B, and fig. S7, A to D). The regulatory networks at the different time points were highly dynamic. For example, the TFs in the GW6 network, including LHX2 and ISL1, which are required for early retinal development (3537), were initially highly expressed. However, during development, the expression and enrichment levels of these TFs were reduced. In contrast, in the GW20 network, many known TFs, such as CRX, NR2E3, and VSX2, were increasingly enriched, confirming their important roles in photoreceptor maturation at the late stage. NFIB and THRA were also enriched in the TF network in the late stage and had connections with other TFs involved in retinal development (Fig. 5, A and B). Since TFs interact with different specific TFs to expand their regulatory repertoire and perform regulatory functions, the edge (connection) counts of each TF may represent its importance in regulating retinal development. To better represent the importance of TFs in a network, we defined the connection score of each node in the network as its edge counts multiplied by the SD of its expression (Fig. 5, C and D, and fig. S7, E to H). For example, TFs with the top connection score, such as VSX2, NR2E3, and CRX, are well-known regulators in retinal development. NFIB and THRA were also observed with high connection score, suggesting that NFIB and THRA are also important in retinal development. The TF networks from the human retinae and ROs were highly correlated from early to late developmental time points (Fig. 5E). However, the TF networks in the middle stage showed relatively lower correlations, which may be due to the distinct C4 chromatin accessibility (Fig. 2A) between human retinae and ROs.

(A and B) Cis-regulatory networks of TFs (nodes) in human retinae GW20 (A) and ROs w23 (B). Circle groups from inner to outer represent different time points. Arrow on edge from node X to node Y indicates that TF-X regulates TF-Y by binding to the promoter site of the latter. Size of each node indicates TF enrichment, and color of each node indicates TF expression levels in that stage. Connection types indicate Pearson correlation between gene expression profiles of connected TFs. (C and D) Ranking of the connection score in human retinae GW20 (C) and ROs w23 (D) networks. The connection score of each node was defined as SD of its expression multiplied by its degree. (E) Similarity of human retinal and RO networks in different developmental stages. We selected GW6/w6, GW10/w10, and GW20/w23 to represent the early, middle, and late stages of retinal development and calculated their similarity score, respectively.

To determine the distinct epigenetic modifications during human and murine retinal development, mouse DHS-seq data at three time points [embryonic day (E14.5), postnatal day 0 (P0) and P7] were downloaded from ENCODE, which can be clustered into five clusters (MC1 to MC5) (fig. S8A). There was no GO term enriched in MC1. The GO terms of MC2 and MC3 showed that they were involved in stem cell proliferation and regulation of cell development, similar to C1 and C2 in Fig. 2A. MC4 was involved in neurogenesis similar to C4, and MC5 was required for visual perception similar to C5. To decipher the similarity between human and murine retinal development in chromatin accessibility, we chose the top 500 peaks in each cluster and then applied GREAT to obtain a list of genes regulated by these ATAC-seq or DHS-seq peaks. The ratio of overlapping genes from human and mouse clusters was calculated (fig. S8B). The results indicated that genes in C1 and C2 were highly overlapped with MC2 and MC3, and genes in C4 and C5 were overlapped with MC4 and MC5.

Then, we coanalyzed human ATAC-seq data or mouse DHS-seq data with chromatin immunoprecipitation sequencing (ChIP-seq) data in the study by AlDiri et al. (9) during retinal development. Eleven chromatin hidden Markov modeling (chromHMM) states (9) were copy used to systematically annotate the epigenetic states across the C1 to C5 (except C3) and MC2 to MC5 regions during retinogenesis (Fig. 6, A and B). State 1 has active epigenetic marks, states 2 and 3 are predominantly enhancers, and state 4 marks bivalent promoters. State 5 is defined by PolII binding, and states 6 and 7 are consistent with gene bodies (H3K36me3). State 8 is a polycomb-repressed chromatin (H3K27me3) outside of the promoter or enhancers. State 9 is empty chromatin, and state 10 marks the H3K9me3-repressed chromatin. State 11 is marked by the insulator protein CCCTC-Binding Factor (CTCF). The results revealed that in murine retinal development, the chromatin accessible sites were mainly regulated by the active promoter/enhancer marks (state 2), whereas the modifications on human genome were diverse. In human retinal development, the active promoter/enhancer marks (states 2 and 3) were involved in C1 and C2 regulation, which progressively decreased during development. States 1 and 4 highly marked C4, and C5 was mainly marked by state 2. It was likely that active epigenetic states were highly associated with chromatin accessibility during both human and murine retinal development. A similar phenomenon was also detected in cell type markers, such as retinal progenitor marker RAX, rod photoreceptor marker NR2E3, cone photoreceptor marker RXRG, and Mller cell marker GLUL (fig. S8C). The peaks from either ATAC-seq or DHS-seq in these markers were mainly modified by active states, such as states 1 and 2, during both human and murine retinal development.

(A and B) Heat map of different ChromHMM state enrichment in each cluster during human (A) and murine (B) retinal development. Each column is a sample, and each row is a ChromHMM state. Color scale shows the relative enrichment. Each state is used to represent the ChromHMM states (rectangle on the right). (C and D) Heat map of H3K4me1, H3K4me3, and H3K27me3 signals for differential regulatory elements in each cluster during human (C) and murine (D) retinal development. Each column is a sample, and each row is a peak region. Color scale shows the relative ChIP-seq peak intensity centered at the summit of each peak. (E) Significant GO terms enriched in bivalent subgroup and H4K4me3-only subgroup peaks using GREAT v3.0.0. The number of genes enriched in GO terms is shown in the parentheses. (F) Violin plot representing H3K4me1 ChIP-seq peak intensity in bivalent subgroup peaks and H4K4me3 subgroup peaks. (G) TF motifs enriched in bivalent subgroup peaks, with P values estimated from HOMER v4.8. (H) Normalized H3K4me3 and H3K27me3 profiles at NFIB and THRA loci during human retinal development. All signals were obtained from the UCSC genome browser.

The bivalent modifications (state 4) marked C4 peak regions specifically in human retinal neurogenesis but not in mouse MC4. To clearly present the dynamic changes of different histone modifications during both human and murine retinal development, we calculated the signals of histone modifications in each cluster (Fig. 6, C and D). The histone modification signals of H3K4me3 and H3K27me3 were enriched in C4 open regions. However, no such notable bivalency modifications were enriched in mouse MC4. These data suggested that the bivalent H3K4me3 and H3K27me3 modifications are distinguished between human and mouse during retinal neurogenesis, which indicate that developing human retina had a more dedicated epigenetic regulation than mouse due to the co-operation of these histone modifications on genome. The bivalent domains were considered to poise the expression of developmental genes, which allowed timely activation while maintaining repression in the absence of differentiation signals (38), matching the critical role of C4 in neurogenesis.

Next, we divided C4 into two subgroups, namely, bivalent subgroup (H3K4me3 and H3K27me3) and H3K4me3-only subgroup, according to the enrichment of different histone modifications in peak regions (Fig. 6E). GO analysis found that the bivalent subgroup was significantly associated with organ development, generation of neurons, and developmental process, suggesting the important role of bivalency in neurogenesis. The H3K4me3-only subgroup was enriched in phosphorylation and guanosine triphosphatase (GTPase)mediated signal transduction, which were involved in general biological process. As expected, we observed H3K4me3-only enrichment in wildly expressed gene PDK2, which functions as a mechanotransducer that stimulates an increase in intracellular calcium in response to fluid flow (39), whereas the bivalent domain of H3K4me3 and H3K27me3 was detected on the developmental gene BMP8B (fig. S8, D and E), further confirming the important role of bivalent domains in neurogenesis. H3K4me1 is one of the critical modifications for neurogenesis (9). Consistent with this, the C4 bivalent subgroup had more H3K4me1 signals than the C4 H3K4me3-only subgroup (Fig. 6F), further confirming the key role of the C4 bivalent subgroup in neurogenesis. Using motif analysis, we predicted the TFs that regulated the motif with bivalency domains (Fig. 6G). Well-known developmental TFs (OTX2/CRX) and proliferation TFs (c-Myc) were enriched in the bivalent subgroup, which are crucial for various regulations of retinal neurogenesis. Since we determined the role of NFIB and THRA in retinal development, we further investigated the histone modifications around their chromatin regions (Fig. 6H). As expected, NFIB and THRA were bivalently modified with H3K4me3 and H3K27me3, further confirming that these factors were involved in retinal neurogenesis. Together, the bivalent histone modifications in C4 were highly associated human retinal neurogenesis but were relatively weak or missing in mice.

We next used GREAT to decipher the key signaling pathways that were differentially activated during human and murine retinal development (fig. S9, A and B). In early human retinal development, the heparan sulfate proteoglycan (HSPG)/fibroblast growth factor (FGF) signaling pathway was enriched. In agreement, the FGF pathway played a number of roles in eye development, including patterning of the optic vesicle, proliferation and differentiation of progenitor cells, and survival of neurons and photoreceptors. Cell surface heparan sulfate (HS) acts as a co-factor for FGF signaling, forming a trimeric complex with FGF and the FGF receptor. It is therefore expected that the HSPG/FGF pathway was discovered in human retinal development. In the early murine development, several known pathways were identified to be involved in retinal development, including Notch, Wnt and E-cadherin pathways. Notch signaling is an important component of RPC maintenance and Mller cell specification during development. Wnt signaling pathway is a known key regulator of optic vesicle establishment, cornea and lens development, and maintenance of retinal stem cell and neuronal specification. Here, histone deacetylase (HDAC) pathway was also emerging as an important regulator for early retinal development in our pathway analysis. Histone acetylation is a posttranslational modification that leads to changes in chromatin structure and transcription repression, which can regulate retinal fate determination. The roles of HDACs in retinal development need further study. In the middle stage of retinal development, pathways including neuronal system, axon guide, and adenylate cyclase activating were enriched. In the late retinal development, we identified a visual transduction pathway, an Na+/Cl-dependent neurotransmitter transporter pathway, and so on, which related with phototransduction or synaptogenesis. The chromatin accessibilities of the genes involved in different signaling pathways matched with their role in retinal development (fig. S9, C and D). The average expression levels of the genes in each pathway were shown, which matched with their functions in retinal development (fig. S9E). Combined, we were able to generate robust genomic, transcriptomic, and epigenomic datasets, which provided a foundation for future studies for retinal development.

Here, we performed a comprehensive assessment of chromatin accessibility and transcriptional changes during human retinogenesis in vivo and in RO differentiation in vitro and revealed stage-specific chromatin dynamics, which regulate human retinogenesis in line with global transcriptional changes. We reconstructed the transcriptional regulatory network and signal pathways regulating human retinogenesis. Notably, we also identified TFs, NFIB, and THRA involved in retinal development, validated by in vitro gene manipulation in the ROs. Therefore, our study provides valuable data for studying human retinal and RO development and a viable framework to optimize in vitro RO differentiation. Moreover, we showed the difference in epigenetic regulation between human and mice. This kind of difference probably contributes gene expression pattern and timing, giving the species difference in retinal development. Therefore, this study gives valuable information to understand species-specific epigenomic regulation.

In our study, we established a temporal-correlation relationship between human retinal and RO development according to epigenetic and transcriptomic profiles (Figs. 1D and 2D). ROs recapitulated the time courses of retinal morphogenesis, retinal neurogenesis, and photoreceptor differentiation of human retinae in the early, middle, and late stages. Hence, our study provided a correlation time frame for the study of stage-specific human retinal development in the RO system. The high transcriptome and chromatic accessibility similarities between human retinae and ROs indicate that ROs are a good model to study human retinal development. Likewise, the human retinal epigenomic and transcriptomic data provide molecular insights for the further improvement of RO differentiation. It is worth noting that the distinct C4 pattern in developing human retina could be related to the complexities of cell types and differential processes in human retinae. Thus, to improve the RO culture, further studies should focus on the DEGs related to C4 particularly.

The transcriptional regulatory networks were reconstructed in both human retinae and ROs. In these networks, we observed many known key TFs for human retinal development, such as OTX2, NR2E3, and ASCL1, which are also critical for retinogenesis in murine. Therefore, the TFs regulating retinal development are conserved among humans, murine, and ROs. We also observed that the TF networks were highly correlated between the developing human retina and ROs, further confirming that the RO system is a good model to study retinal development. Moreover, NFIB and THRA were identified as potential regulators involved in retinogenesis. Thus, the transcriptional regulatory network expands our understanding of molecular regulation during human retinal development. Previous studies have demonstrated that NFIB plays an important role in regulating neural progenitor cell proliferation and differentiation in the cortex (40). Nfib function was very recently verified in regulating cell cycle and the differentiation of late-born retinal progenitors in mice, further supporting our prediction of the function of NFIB, and suggested the reliability of our data analysis (41). In our study, loss of NFIB at the middle retinal differentiation stage reduced the expression of photoreceptor-associated genes. From pathways and motif analysis, we identified that PROM1 and NR2E3 might be the potential targets of NFIB, partially explaining how NFIB regulates human retinogenesis. The thyroid hormone receptors TR1 and TR are encoded by the genes THRA and THRB, respectively. THRB plays important roles in cone photoreceptor development (42, 43). However, whether THRA is also involved in human retinal development remains unclear. In our transcriptional regulatory network, we found that THRA may interact with NR2E3, VSX1, and CRX, which are well-known regulators in retinal development. We also demonstrated the role of THRA in retinal development via RO molecular manipulations. The function of THRA in retinal development, which has not been reported previously, may be due to the compensatory effects of THRB. The genesis of Mller cells and photoreceptors in ROs detected by immunostaining started after w14, around w17 (15). Here, we knocked down NFIB and THRA at ~14-week-old ROs, which mainly contained retinal progenitors but limited cell numbers of Mller cells (RLBP+) and photoreceptors (GNAT1+ or RHO+). Therefore, it is highly possible that NFIB and THRA mainly function in regulating retinal progenitor differentiation, thereby affecting both the photoreceptor and Mller differentiation.

Histone modifications are crucial for the control of gene expression, cell fate decisions, and differentiation. Many chromatin regions in embryonic stem cells and early embryonic development harbor a distinctive histone modification signature that combines the active H3K4me3 and the repressive H3K27me3 marks (44). These bivalent domains are considered to poise the expression of developmental genes, allowing timely activation while maintaining repression in the absence of differentiation signals. Here, in human retinal development, C4 is bivalently modified and associated with human retinal neurogenesis only, demonstrating a fine-tuning on the gene expression that associated human neurogenesis. Thus, these bivalent features in C4 may facilitate neurogenesis via timely gene activation and silencing. Moreover, cross-analysis with ATAC-seq, RNA-seq, and pathway analysis highlighted numerous signaling pathways, which seemed to be differentially activated in retinal development. The differential activation of these pathways is consistent with changes in the expression of key genes in long retinal development, providing potential regulators involved in retinal development. Thus, our data provided a large scope of data sources for further molecular study underlying retinal development.

In summary, we provided a comprehensive view of the chromatin landscapes that accompany human retinal and RO development; established a comprehensive resource for temporal and molecular correlations between human retinal and RO development; discovered TFs for human retinal development; and reconstructed the transcription regulatory network and signaling pathways, which greatly expand our understanding of human retinal development and provide a roadmap for further studies.

Human embryo collection was approved by the Reproductive Study Ethics Committee of Beijing Anzhen Hospital (2014012x). All embryos were obtained with written informed consent signed by the patient who had made the decision to legally terminate her pregnancy. Informed consent confirmed that the patients were voluntarily donating embryos for research on human embryonic development mechanisms with no financial payment. The deidentified fetal retinae were collected with patient informed consent in strict observance of the legal and institutional ethical regulation approved by the Institutional Review Board (ethics committee) at the Institute of Biophysics, Chinese Academy of Sciences. All samples used in these studies had never been involved in previous procedures (drugs or other tests). All protocols followed the Interim Measures for the Administration of Human Genetic Resources administered by the Chinese Ministry of Health.

Fetal retinae were collected in ice-cold artificial cerebrospinal fluid, which included 125.0 mM NaCl, 26.0 mM NaHCO3, 2.5 mM KCl, 2.0 mM CaCl2, 1.0 mM MgCl2, and 1.25 mM NaH2PO4 (pH 7.4), bubbled with carbogen (95% O2 and 5% CO2). Retinae were gently cut into small pieces, and tissue samples were centrifuged for 5 min at 500g at room temperature (RT). The supernatant was removed followed by the addition of 900 l of 0.25% trypsin-EDTA (Thermo Fisher Scientific, 25200114) with 5 l of DNase I (Thermo Fisher Scientific, EN0521) for digestion for 15 min at 37C. Shaking and gentle pipetting were performed at 5-min intervals. We added 100 l of fetal bovine serum (FBS; Thermo Fisher Scientific, 10270) to stop digestion. Samples were centrifuged and washed with 1 ml of Dulbeccos phosphate-buffered saline (DPBS; Thermo Fisher Scientific, 14190250). We collected ~50,000 cells for ATAC-seq and ~1 million cells for RNA-seq.

The BC1eGFP (enhanced green fluorescent protein) (45) hiPSC line was obtained from L. Cheng (Johns Hopkins University, Baltimore, MD, USA), with verified normal karyotype and was contamination free. hiPSCs were maintained on Geltrex-coated plates (Thermo Fisher Scientific, A1413302) with TeSR-E8 medium (STEMCELL Technologies, 05940) in a 37C, 5% CO2 humidified incubator. Cells were passaged with ACCUTASE (STEMCELL Technologies, 07920) every 4 to 5 days at ~70% confluence, and autodifferentiated cells were marked and mechanically removed before passaging. We added 10 M Y-27632 (STEMCELL Technologies, 72304) into the TeSR-E8 medium on the first day after passaging.

The hiPSC line was induced to differentiate into ROs, as described previously (15). Briefly, on D0, hiPSCs were treated with dispase (STEMCELL Technologies, 07923) until the edges of the clones began to curl, after which they were scraped into small pieces and cultured in suspension with mTeSR1 medium (STEMCELL Technologies, 05850) and 10 M blebbistatin (Sigma-Aldrich, B0560) to induce aggregate formation. Aggregates were gradually transitioned into neural induction medium (NIM) containing Dulbeccos Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) (Thermo Fisher Scientific, 11330), 1% N2 supplement (Thermo Fisher Scientific, 17502), 1 MEM Non-Essential Amino Acids Solution (NEAA) (Thermo Fisher Scientific, 11140), heparin (2 g/ml; Sigma-Aldrich, H3149), and 1% antibiotic-antimycotic (Thermo Fisher Scientific, 15240) by replacing the medium with a 3:1 ratio of mTeSR1/NIM on D1, 1:1 on D2, and 100% NIM on D3. On D7, aggregates (average size of 250 50 m) were seeded onto Geltrex-coated dishes containing NIM at an approximate density of 10 aggregates/cm2 and switched to retinal differentiation medium (RDM) on D16 containing 70% Dulbeccos Modified Eagle Medium (DMEM) (Thermo Fisher Scientific, 11965) and 30% Hams F-12 Nutrient Mixture (F-12) (Thermo Fisher Scientific, 11765) supplemented with 2% B27 supplement (Thermo Fisher Scientific, 12587010), 1 NEAA, and 1% antibiotic-antimycotic. On D28, the neural retina domains were manually detached with a sharpened Tungsten needle under an inverted microscope and then collected and cultured in suspension in RDM. On D42, RDM was transitioned into retinal maturation medium (RMM) containing 60% DMEM, 25% F-12, supplemented with 10% FBS (Thermo Fisher Scientific), 100 M taurine (Sigma-Aldrich, T0625), 2% B27, 1 NEAA, 1 GlutaMAX supplement (Thermo Fisher Scientific, 35050), and 1% antibiotic-antimycotic. We freshly added 1 M retinoic acid (Sigma-Aldrich, R2625) to the RMM when the medium was changed twice a week.

Human retinae were fixed in 4% paraformaldehyde (PFA; Sigma-Aldrich, 16005) for 2 hours at RT, and ROs were fixed in 4% PFA for 30 min at RT. All samples were washed in DPBS (three times for 10 min), dehydrated with a sucrose gradient (15% for 30 min at RT and 30% overnight at 4C), and embedded in Tissue-Tek OCT Compound (Sakura, 4583) for freezing. Samples were sectioned (10 m unless otherwise stated), air dried for 1 hour, washed in DPBS (three times for 10 min), blocked in 10% bovine serum albumin (BSA; Sigma-Aldrich, B2064) in DPBS with 0.25% Triton X-100 (Sigma-Aldrich, T9284) for 1 hour at RT, and incubated with a primary antibody in 10% BSA in DPBS with 0.25% Triton X-100 at 4C overnight. The next day, slides were washed in DPBS (three times for 10 min) and incubated with corresponding species-specific Alexa Fluor 568 or Alexa Fluor 647conjugated secondary antibodies (1:500; Thermo Fisher Scientific, A-11036 and A-21245, respectively) in DPBS for 2 hours at RT. The slides were incubated in 4,6-diamidino-2-phenylindole (DAPI) (1:1000; Thermo Fisher Scientific, D1306) in DPBS for 5 min, washed in DPBS (three times for 10 min), and cover slipped. Primary antibodies against the following proteins were used at the indicated dilutions: GNAT1 (1:200; Santa Cruz Biotechnology, sc-389), RCVRN (1:100; Millipore, AB5585), and NR2E3 (1:100; R&D Systems, PP-H7223-00). Fluorescence images were acquired with an LSM 800 confocal microscope (Zeiss).

shRNA sequences of targeted genes (table S1) were synthesized by Tsingke Biological Technology and cloned into shRNA expression vector pAAV-U6-shRNA-CMV-mKate2-SV40, and pAAV-U6-shRLuc-CMV-mKate2-SV40 vector with luciferase shRNA (gtgcgttgctagtaccaacttcaagagagttggtactagcaacgcactttttt) was used as control. The complementary DNA (cDNA) of the CRX gene for overexpression was cloned into the pEF1-cDNA-IRES2-mKate2 vector, and the pEF1-IRES2-mKate2 vector without CRX cDNA was used as control. Primers used are listed in table S1. High-quality vectors were extracted using the NucleoBond Xtra Maxi EF Kit (Macherey-Nagel, 740424.50), with a final concentration of 1 g/l used for electroporation. In all experiments, electroporation was performed on both control and experimental groups. ROs for electroporation were manually cut into ~500-m (diameter) pieces under an inverted microscope, equally distributed to both control and experimental groups, and resuspended in the Human Stem Cell Nucleofector Kit 1 (Lonza, VPH-5012). Ten pulses of electroporation were performed on both sides of the small balls under the following parameters: square wave, 35 V, 1 Hz, and 5% duty.

Total RNA was isolated from samples with TRIzol (Thermo Fisher Scientific, 15596018) and converted into cDNA with a PrimeScript RT Master Mix (TaKaRa, RR036A). FastStart Essential DNA Green Master (Roche, 06924204001) was then used for qRT-PCR analysis, with RNA-seq performed on an Illumina HiSeqXten-PE150. Primer sequences for qRT-PCR are shown in table S1.

ATAC-seq was performed as described previously (11, 46). Briefly, a total of 50,000 cells were washed twice with 50 l of cold DPBS and resuspended in 50 l of lysis buffer [10 mM tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, and 0.1% (v/v) NP-40 substitute (Sigma-Aldrich, 11332473001)]. The suspension of nuclei was then centrifuged for 10 min at 500g at 4C, followed by the addition of 50 l of transposition reaction mix (10 l of 5 TTBL buffer, 4 l of TTE mix, and 36 l of nuclease-free H2O) of TruePrep DNA Library Prep Kit V2 for Illumina (Vazyme Biotech, TD501). Samples were then incubated at 37C for 30 min. DNA was isolated using the QIAquick PCR Purification Kit (QIAGEN, 28106). ATAC-seq libraries were first subjected to five cycles of preamplification using NEBNext High-Fidelity 2X PCR Master Mix (New England Biolabs, M0541S). To determine the suitable number of cycles required for the second round of PCR, the library was assessed by qPCR as described previously (11) using NEBNext High-Fidelity 2X PCR Master Mix with SYBR Green I Nucleic Acid Gel Stain (Thermo Fisher Scientific, S7563) and then PCR amplified for the appropriate number of cycles. Libraries were purified with the QIAquick PCR Purification Kit. Library quality was checked using the High Sensitivity DNA Analysis Kit (Agilent, 5067-4626). Last, 2 150 paired-end sequencing was performed on an Illumina HiSeq X-10.

FASTQ files were evaluated for quality control using FastQC (v0.11.5) (www.bioinformatics.babraham.ac.uk/projects/fastqc/). Sequence alignment was performed using STAR (v2.5.2a) with reference assembly hg19. We estimated gene expression levels using reads per kilobase of transcript per million mapped reads (RPKM) values. DEGs were filtered by an RPKM value of >5 for one stage and an absolute value of log2 fold change >1 between any two groups. GO analysis was performed using David v6.8. The RNA-seq data of the developing human retina were obtained from the previous study (8), and we defined D52/D54, D57, D67, D80, D94, D105, D115, D125, D132, and D136 as GW7, GW8, GW10, GW11, GW13, GW15, GW16, GW18, GW19, and GW20.

Primary data were processed as described previously (19). In simple terms, we removed adapter sequences and then mapped reads to hg19 using Bowtie2. The PCR duplicates and chromosome M were removed. The uniquely mapped reads were shifted +4/5 base pair (bp) according to the strand of the read. All mapped reads were then extended to 50 bp centered through the cleavage position. Peak calling was performed using MACS2 with options - f BED -g hs, -q 0.01, --nomodel, --shift 0.

ATAC-seq data quality was comprehensively studied in the previous work (17). Briefly, we used several parameters to evaluate data quality, including number of raw reads, overall alignment rate, final mapped reads, final mapped rate, percentage of reads mapped to chromosome M, percentage of reads mapped to repeat regions (black list), percentage of reads filtered out by low MAPQ score, percentage of PCR duplicates, TSS enrichment score (reads enriched at 2 kb around TSS versus background), and read length distribution.

Peak calling was performed using MACS2 from all sample reads. The number of raw reads mapped to each peak at each condition was quantified using the intersectBed function in BedTools. Raw counts in peaks were normalized using the DESeq package in R. Peak intensity was defined as the log2 of the normalized counts. Samples were then grouped into 17 categories (30 samples; RO: w0, w2, w4, w6, w10, w15, w23, and w30; human retina: GW6, GW10, GW11, GW12, GW14, GW15, GW20, GW24, and GW25). First, to remove the genomic regions dominated by hiPSCs, we compared peaks between RO w0 and other time points (w2 to w30) to remove peaks with log2 fold change >1 on w0 and SD <1 on other time points. Significance analysis was then performed by pairwise comparison with eight categories of RO samples and nine categories of human retinal samples using DESeq with P < 0.01, false discovery rate (FDR) < 0.01, log2 fold change >1, and intrinsic analysis with z score >1. We lastly obtained 10,563 differential accessible peaks. We used the long-distance peaks (located 1 kb outside the TSS of the gene) to calculate the correlation between samples. Unsupervised clustering was performed using Cluster 3.0 and visualized in Treeview. GO and other enriched functions of cis-regulatory regions were performed with GREAT.

Intrinsic analysis followed the steps described in the previous research (10). We defined correlation matrix C, where Cp,q is the Pearson correlation between samples p and q where all peaks were included. Similarly, we defined correlation matrix Ci, where Cip,q is the Pearson correlation between samples p and q where all peaks except for peak i were excluded. We defined delta matrix, deltaCi = C Ci. We defined wbScorei = average (deltaCireplicates) average (deltaCinonreplicates). Replicates were defined as samples at the same time point, and nonreplicates otherwise. For peak i, the greater the wbScorei, the less variance the peak intensity was within the replicates and the greater variance within nonreplicates. We then calculated the average and SD of all wbScore (from I = 1 to N). We defined z score = (wbScorei average (wbScorei=1,N))/SD (wbScorei=1,N).

Details of protocols and standards for DHS-seq are described by ENCODE (www.encodeproject.org/). All replicates of DHS-seq samples were combined before analysis for the D74 (DHS-GW11) and D125 (DHS-GW18) time points. The Bowtie2 algorithm was implemented to align the reads to the human (hg19) reference genome (with option --very-sensitive). PCR duplicates, reads mapped to repeated regions, and chromosome M were removed.

To correlate the developmental stages between human retina and RO, we applied OE-DTW analysis (21). DTW is a popular technique for comparing time series. The rationale behind DTW is that given two time series, they should be stretched or compressed locally to make one resemble the other as much as possible. We used the R package DTW on expression profiles of human retinal development spanning from GW6 to GW25. The analysis was performed on the 3235 genes from the human RNA-seq data to find an optimal alignment between the human retinal and RO development.

The TF motif enrichment analysis was performed using HOMER with options: findmotifs.pl input.fa fasta output. To obtain genes that may be regulated by a certain TF, we overlapped all the binding site of TFs with the open sites. Genes with TF binding sites in the promoter region were then considered to be possible regulated genes.

For footprint, we adjusted the read start sites to represent the center of the transposons binding. Previous descriptions of the Tn5 transposase show that the transposon binds as a dimer and inserts two adaptors separated by 9 bp. Therefore, we modified the reads aligned file in the SAM format by offsetting +4 bp for all the reads aligned to the forward strand and 5 bp for all the reads aligned to the reverse strand. We then converted a shifted base SAM file to the BAM format and had the BAM file sorted using SAMtools. We overlaid TF binding sites with reads in each sample of the C4 and C5 peak regions. We then averaged the overlaid read counts of a 150-bp genomic region centered by the motif sites for motif footprints.

To study the regulatory mechanisms of TF NFIB, we predicted the potentiality of NFIB to bind to retinal-related genes. First, we selected a total of 35 genes enriched in the highlighted term in fig. S6A. We expanded each gene with the upstream of TSS by 10 kb and the downstream of gene transcription termination site by 5 kb. Next, we overlapped the binding site of NFIB in the peak regions of our ATAC-seq with extended gene regions. To better compare the possibility of these genes bonded by the NFIB motif, we calculated the flanking accessibility and the footprint depth of the motif binding regions. This is based on previous work (47). We first defined two key relative positions: (i) The footprint base is the region encompassing the very center of the motif and is defined as a motif binding site, and (ii) the footprint flank is the region immediately adjacent to the TF binding site and is defined as the region between the end of the footprint base and 100 bp away from the motif end. The accessibility of the motif region and the flank region was calculated. The higher value for footprint depth and the lower value for flanking accessibility indicate strong factor occupancy. We defined binding potential = flanking accessibility/footprint depth to characterize the binding potential of a gene region.

To map the regulatory network throughout the retinal developmental process, we selected human GW6, GW10, and GW20 and RO w6, w10, and w23 to represent the early, middle, and late stages of retinal development, respectively. According to Fig. 2A, we assigned motifs enriched in the C1 and C2 to the early stage and motifs enriched in C4 and C5 to the late stage. Because the development of ROs in the middle stage appeared to be slower than that of the human retina in C4, we assigned motifs enriched in C2 and C4 to the human middle stage and motifs enriched in C2 to the RO middle stage. First, we used HOMER to find the TFs that were bound to each cluster (P < 1 1020). A TF with a higher gene expression level on a time point than the average expression of all time points was considered as a member of the regulatory network of this time point, and then we constructed a transcriptional regulatory network. We defined the promoter region of TF-Y as going from the upstream 10 kb to the downstream 1 kb of TSS. If TF-X binds to the promoter of TF-Y, then we assumed that TF-X regulates TF-Y. The size of each node indicates the TF enrichment in that stage, and the color of each node indicates the TF expression in that stage. The correlation between TF-X and TF-Y expression (CX,Y) was calculated: CX,Y > 0.5, positive correlation; CX,Y < 0.5, negative correlation; 0.5 < CX,Y < 0.5, no correlation. We defined the connection score of each node in the network as its edge counts multiplied by the SD of its expression. To measure the extent of consistency between human retinae and ROs, we compared the similarities of their regulatory networks. We defined similarity score: S = 1 D (D = 0.5 N/M + 0.5 (I 0.5)/J), where D values represent differences between human retinae and ROs over the same time period. The differences in regulatory networks come from two aspects. One is that the two regulatory networks share some common TFs, so we used the ratio of the different connections (N) and all connections (M) in the same TF to represent this difference. The other is derived from the different TFs. We divided half the number of different TFs (I) by the number of all TFs (J). We assumed that they may share the same contribution to differences in regulatory networks; therefore, we multiplied the respective coefficients by 0.5.

DHS-seq data for mouse retinae (E14.5, P1, and P7) from ENCODE (www.encodeproject.org/) were analyzed. The Bowtie2 algorithm was implemented to align the reads to the mouse (mm9) reference genome (with option --very-sensitive). PCR duplicates, reads mapped to repeated regions, and chromosome M were removed. After peak calling and DESeq normalization, significance analysis was then performed on adjacent time points with P < 0.01, FDR < 0.01, log2 fold change >2. We lastly obtained 8967 differential peaks. Unsupervised clustering was performed using Cluster 3.0 and visualized in Treeview. GO and other enriched functions of cis-regulatory regions were performed with GREAT. To identify chromatin states, we used the ChromHMM software (v.1.06) according to the previous paper (48). Neighborhood enrichment command was used to calculate the enrichment of different chromatin states in cluster peak regions.

We calculated the signals of H3K4me3 and H3K27me3 modifications in each peak of C4 at GW13 and GW14. We defined average signals of a modification (m) in one peak region (g) as S (mg). If S (mg) > 1, then the peak region g enriched modification m. We divided the peaks of C4 into two subgroups, namely, H3K4me3-only subgroup and bivalent subgroup according to the enrichment of different histone modifications in peak region. If a peak region simultaneously enriched with both modifications of H3K4me3 and H3K27me3, then the peak is in a bivalent state, and if enriched with the H3K4me3 but not H3K27me3 modification, then the peak is H3K4me3-only state.

We extracted the fluorescence intensity of RCVRN by ImageJ software, following the ImageJ User Guide. Corrected total cell fluorescence (CTCF) of each calculated cell (mKate2+ cells and mKate2-RCVRN+ cells) in the same slice was compared with the mean CTCF of mKate2-RCVRN+ cells to normalize the CTCF between different slices. The normalized CTCF of mKate2+ cells in both the control and NFIB_KD groups was compared with the mean of the normalized CTCF of mKate2+ cells in the control group, and then the relative intensity of the RCVRN in each cell was obtained.

Statistical significance was analyzed with unpaired two-tailed t tests or one-way analysis of variance (ANOVA). A value of P < 0.05 was considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Data are presented as means SEM as indicated in the figure legends. All statistical analyses were performed in GraphPad Prism v7.00.

Go here to read the rest:
Chromatin accessibility analysis reveals regulatory dynamics of developing human retina and hiPSC-derived retinal organoids - Science Advances

Dr. Shereene Idriss Shares 2020 Filler Innovations and Trends – coveteur.com

Dr. Shereene Idriss explains one of the biggest factors thats aging you that you may never have heard of before.

As the saying goes, new year, new you, right? It depends on who youre speaking with, but if youre asking your dermatologist, they might explain that its not that simple. Theres no magical serum or cream that can completely turn back the hands of time, but with the recent innovations in cosmetic procedures, it is easier than ever to help your skin age gracefully. Fillers especially are one of the most popular options for people who are looking to lift, firm, or otherwise minimize obvious signs of aging, like fine lines and wrinkles.

There are always new research and innovations within the world of dermatology, so we sat down with top NYC dermatologist Dr. Shereene Idriss to get the 411 on the most exciting breakthroughs for 2020. From the two new filler formulations to the most requested cosmetic proceduresplus one of the biggest factors thats aging you that you might never have heard of beforethis is what we can look forward to in the skin-care market in the year ahead.

What has been the most requested procedure in the past few months, and what do you expect to continue throughout 2020?

A lot of jawline addressment, wherein people want a more rigid, firmer, or more defined jawline. Not a different-looking jaw, which I have to re-educate some people aboutyou have to work in sync with the face. A strong jawline definitely saves the face as we age, since our chins and our jawlines sag. But your jawline has to align with your mid-face. It has to co-exist in a way that makes sense.

Why do you think that is becoming such a popular request?

I think its Instagram. Its both a blessing and a curse. People are oftentimes seeing versions of themselves that are maybe not real. But even if you think of the big-name celebrities, like Kim Kardashian or Jennifer Lopez, they have very strong jawlines. They are associating it with being beautiful. Some patients are coming in with that mind-set, versus being an actual candidate for that procedure. Its really up to the physician to be true to themselves so that people dont start morphing into these caricatures were seeing. [Some of] these crazy jawline fillers almost look like theyve gotten an implant. It really doesnt match the face.

What about in terms of filler innovations?

There was a rumor about Volite [coming] out in 2020. Itll be interesting to see how a lightweight hyaluronic filler can replenish moisture in the dermis. [Its] a lighter effect that helps with the texture of the skin. I also heard that Revance, the approved form of Teoxanewhich is a resilient form of hyaluronic acid, meaning its longer-lastingitll be interesting to see how well incorporate it when using various fillers in the face. Theyve been using it outside of the United States for a while now. With regards to Teoxane, they have four different ones, three of which have been FDA-approved in the US, and theyre all indicated for different areas of the face. The fourth one is still going through approval. Its like having different paintbrushes in your toolbox.

Is there anything that doesnt yet exist that youre hoping to see developed within the world of fillers?

I think that facial anatomy is so complicated when it comes to structure. There is no miracle product, like in skin care. I dont think it would be good to have a filler that could address all of your problems, because when you think of the face, you want everything to work a little differently. You want it to be sturdier around the jawline to hold the face up, or along your cheekbones. You want it to be malleable along the cheeks or where you smile, so your face can move. It doesnt make sense to have a miracle filler, in my mind.

What about longer-lasting filler?

It makes sense to me to have a long-lasting filler; however, it comes with a caveat. I dont think that having super long-lasting filler is really beneficial because our bone structure changes so much as we age, especially in our 40s. So if you have a long-lasting filler over an ever-changing face, things can start to look wonky over time.

If you look at [cheek] implants, you would have these patients come in, and there are a few who are a bit older because its not as trendy now or en vogue, but their cheeks are sitting [higher] and everything is aging around it, [so] they have a Cruella de Vil look because its not moving. With an aging face, you have to be malleable; you have to work with an aging face. You cant be rigid.

Illustration: Meghann Stephenson... Read More

How much bone density are you losing when you start to age? What is the average percentage per decade?

It starts in your 20s. There is a study from 2012 [stating that] bone structure reduces about 90 percent after menopause. Aging is associated with the decrease in the growth hormone secreted in the pituitary gland. Its decreasing at 14 percent per decade. I dont know if this is associated with bone resorption, but its significant. It cant be overlooked. [Which is why] I feel strongly about not using semi-permanent fillers in the face. I think you can use them in different areas of the face to your benefit, but in the midface, area thats actively changing, you have to grow with the face.

Along with jaw filler, what is another type of treatment that youre seeing more often with your patients?

Younger and younger women are asking for under-eye [filler]. I think it has to do with the filter effect [thats] going on, where people think they shouldnt have a little line under their eyes when they smile. Id say thats normal. Sometimes you definitely should [explore under-eye filler] if the wrinkle is a little deeper, but Id say those two [are the most popular].

What is the process for using the filler under the eye?

Its a tricky area. I think more people think they need it, that theyve lost volume in the eye area, when really their face is dropping. Its better to lift the face laterally with filler around the eye, in my opinion, without really going for the under-eye filler. There are two ways you can do filler: with a blunt-edge needlea cannulaor a sharp-edge needle. But it really depends on what the physician is comfortable using.

Always [use] a lightweight filler for under the eye. I personally dont do the eye without addressing the rest of the face. If youre scared of fillers, you can always do the PRP [platelet-rich plasma] injections, which take your own blood and separate the growth factors. Its still an invasive procedure, but its coming from yourself.

As fillers have become more socially acceptable, do you think people are shying away from more invasive procedures, or are they fatigued by fillers and are searching for something else long-term?

Im very biased because I only see my patient population. The first question I always ask an older patient is Are you someone who wants to get a face-lift in this lifetime, or are you completely against it? The person who is OK with it, Im looking at their skin quality and anatomy and seeing if theyre a candidate for a face-lift. I would push them to get one, and then we can maintain it when they come back to me. A lot of people ask me to reverse or fix work. I think, unfortunately, there are a lot of people out there who just listen to exactly what their patient wants, and that can result in unnecessary amounts of filler to the face, without thinking about the surgical procedure as a choice.

I always think about whether or not this age [at which to recommend a face-lift] will be pushed back because of all of the advances weve made to tighten and resurface the skin. I think that the age of having to get a face-lift is going to be pushed back over time. [Right now] people start to take it seriously at 55-plus.

What is the average age of the first-time filler user in your practice?

Ive noticed three main peaks. The first one is 30 to 33, where they feel like over the past six months their face has shifted. The second one is 39 to 42, where the change happens more dramatically, maybe over a month or so. And then again, in your late 40s, where I get told over and over again, I woke up one morning and I dont recognize myself. Help. Volume loss starts to happen in your late 20s, early 30s, which makes sense if youre thinking about bone density and all of that. Youve probably lost weight, gained weight, et cetera.

For a client whos coming in and saying I dont understand why I look older, but I do. Please help. What is your strategy?

I really look at the face. When youre looking at aging, its a number of things. Its volume loss; its if you have any built-in wrinkles in your face; its the color of your skin; its how elastic your skin is, and your bone structure. I will start with one and see if it works. Some people want Botox but have no lines. I try to tell them, You dont need it yet. There are women out there that listened to their moms [to take care of their skin] and look like little fairies and look impeccable. But theres always the one beginning sign of [aging].

Photo: Shot on site at 6 Columbus, a Sixty Hotel. On Jonelle: Necklace, Baker & Black,Catbird; Hair, Angela Soto; Makeup, Andriani.

Want more stories like this?

4 Under-the-Radar French Skin-Care Brands You Need to KnowThese 5 Clean Moisturizers Saved My Dry Winter SkinTo Flip or to Lift: The Newest Ways to Get Fuller Lips

Read the original here:
Dr. Shereene Idriss Shares 2020 Filler Innovations and Trends - coveteur.com

Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma – Cancer Network

Early results from a phase I/II trial, published inThe New England Journal of Medicine, found that a majority of patients with either relapsed or refractory non-Hodgkins lymphoma (NHL) or chronic lymphocytic leukemia (CLL) treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.1

Additionally, there was no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline; however, the maximum tolerated dose was not reached.

We are encouraged by the results of the clinical trial, which will launch further clinical studies to investigate allogeneic cord blood-derived CAR NK cells as a potential treatment option for patients in need, corresponding author Katy Rezvani, MD, PhD, professor of stem cell transplantation and cellular therapy at The University of Texas MD Anderson Cancer Center, said in a press release.2

In this study cohort of 11 patients with relapsed or refractory CD-19 positive cancers, participants were given a single dose of cord blood-derived CD19 CAR NK cells at 1 of 3 dose levels. Five of the patients had CLL and the remaining 6 had NHL. All of the patients were treated with a minimum of 3 and a maximum of 11 lines of prior therapy. The first 9 participants treated were given CD19 CAR NK cells that were partially matched according to the individuals HLA type, but protocol allowed the last 2 patients to be treated with no HLA matching.

Eight (73%) of the participants had a response, and of those, 7 (4 with NHL and 3 with CLL) had a complete remission, while 1 had remission of the Richters transformation component, but had persistent CLL. The responses were rapid and observed within 30 days after infusion at all dose levels. The infused CAR NK cells expanded and persisted at low levels for at least 12 months.

According to the researchers, a proportion of patients treated with anti-CD19 CAR T cells have a subsequent relapse, with a 1-year progression-free survival of approximately 30% observed among patients with CLL and 45% seen among those with NHL.

In view of these outcomes, our study allowed for remission consolidation therapy with an immunomodulatory agent, anticancer drug, or hematopoietic stem-cell transplantation at the discretion of the treating physician, the authors wrote. However, the use of post-remission therapy in this study limits our assessment of the durability of response after CAR NK therapy.

Notably, researchers did observe high-grade transient myelotoxicity in the cohort, of which they attributed to the lymphodepleting chemotherapy. However, they were unable to assess whether the CAR NK cells contributed to the myelotoxicity.

Side effects experienced by the patients were primarily related to the conditioning chemotherapy given before cell infusion and were resolved within 1 to 2 weeks, according to Rezvani. Additionally, no patient required admission to an intensive care unit for management of treatment side effects.

Due to the nature of the therapy, weve actually been able to administer it in an outpatient setting, Rezvani said. We look forward to building upon these results in larger multi-center trials as we work with Takeda to make this therapy available more broadly.

References:

1. Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.The New England Journal of Medicine. doi:10.1056/NEJMoa1910607.

2. CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma [news release]. Houston, Texas. Published February 5, 2020. app.bronto.com/public/viewmessage/html/6781/hemm7h92mwb6849npf2js0r4mhnrl/0bd003eb00000000000000000000000df096. Accessed February 6, 2020.

See original here:
Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma - Cancer Network

Physical forces at the interface with biology and chemistry – PLoS Blogs

Cell behaviour, tissue formation/regulation, physiology and disease are all influenced by cellular mechanics and physical forces. The field of mechanobiology has for a long time striven to fully understand how these forces affect biological and cellular processes, as well as developing new analytical techniques. At the same time, the properties of advanced smart materials, such as self-healing, self-reporting and responsive polymers, have been determined by a complex interplay between the thermodynamics, kinetics and mechanics of dynamic bonding strategies. These are tightly connected to the field of mechanochemistry, whichaims to elucidate and harness molecular level design principles and translate these to the bulk material level as emergent properties. At this interface between disciplines lies an emerging and exciting research area that has been strongly facilitated by the collaboration of physicists, chemists, engineers, materials scientists, and biologists.

We had the pleasure of speaking to Kerstin Blank and Matthew Harrington, who have been working on how mechanical forces influence biological systems, molecules and responsive biomaterials, about their views of the field and the recent Multiscale Mechanochemistry and Mechanobiology conference of which PLOS ONE was one of the proud sponsors.

How did you first become interested in this topic?

Kerstin: When I started in this field in 2000, I was mostly impressed by the technical possibilities. I was working with Hermann Gaub, one of the leaders in single-molecule force spectroscopy. I found it fascinating that we could stretch a single biological molecule and observe its response. I did ask myself sometimes if this was just something that physicists like to play with or if one could solve biomedically relevant questions with this approach. Now, almost 20 years later, it has become very evident that a large number of biological systems are regulated by mechanical forces in many different ways.

Matt: My educational background was primarily in biology and biochemistry, but I became fascinated with the capacity of certain biological materials to exhibit self-healing responses in the absence of living cells. I reasoned that this must arise from specific chemical and physical design principles in the material building blocks themselves, and I became obsessed with figuring out how this works. This led me to the self-healing materials community, which was largely populated with chemists and materials engineers, but not so many biologists. When I began to see that many of the same principles at play in synthetic self-healing materials were present in nature, and that in some cases nature was going well beyond the state of the art in synthetic self-healing materials, I realized the enormous potential at the interface of mechanobiology and mechanochemistry. I havent looked back since.

Which areas are you most excited about?

Kerstin: I find it very intriguing how cells utilize mechanical information from their environment and then feed it into intracellular biochemical signalling cascades. Understanding these mechanosensing and mechanotransduction processes requires knowledge of the cellular players and their interactions. But to develop the complete picture, we also need to investigate how cells interact with their extracellular environment. This also involves understanding the microscopic and macroscopic mechanical properties of the extracellular environment. I am highly excited about the development of molecular force sensors that convert mechanical force into a fluorescent signal. This allows for the localized detection of cell traction forces and, in the future, will also enable us to visualize force propagation inside materials that mimic the natural extracellular matrix.

Matt: I am currently most excited about understanding how and why nature uses different transient interactions to control the fabrication and viscoelastic mechanical responses of biopolymeric materials and the potential this has for the development of sustainable advanced polymers of the future. Recent discoveries in the field clearly show that in contrast to traditional polymers, living organisms commonly use specific supramolecular interactions based on dynamic bonds (e.g. hydrogen bonding, metal coordination or pi-cation interactions) to guide the self-assembly and mechanical properties of protein-based materials. The thermodynamic and kinetic properties of these labile bonds enable a certain dynamicity and responsiveness in these building blocks that provides potential inspiration for environmentally friendly materials processing and active/tuneable material properties. These concepts are already being adapted in a number of exciting bio-inspired polymers.

What progress has the field made in the last years?

Kerstin: It is now well-established that cells are able to sense and respond to the elastic and viscoelastic properties of the material they grow in. We have also learned a lot about how the mechanical signal is converted into biochemical signalling on the intracellular side. This is a direct result of many new technological developments, including the molecular force sensors described above. It is further a result of the increasing development of extracellular matrix mimics with well-defined and tuneable mechanical properties and microstructures.

Matt: Due to recent technological advances it is becoming possible to link specific aspects of mechanical material responses directly to structural features at multiple length scales. The better we understand these structure-property relationships, the better we can optimize the material response. This provides an intimate feedback loop that has enabled major breakthroughs in the fields of active matter, including self-healing and self-reporting polymers.

What is the real-world impact?

Kerstin: It is widely accepted that mechanical information plays a key role in stem cell differentiation. It has further been shown that mutated cells, e.g. in cancer or cardiovascular diseases, have different mechanical properties and show alterations in processing mechanical information. Understanding the origin of these changes and being able to interfere with them will have direct impact in disease diagnostics and treatment. Engineering materials with molecularly controlled structures and mechanical properties will further enable the community to direct stem cell differentiation in a more defined manner for applications in tissue engineering and regenerative medicine.

Matt: Aside from biomedical impacts, the insights gained from understanding the structure-function relationships defining the mechanical response of molecules are also extremely relevant for the development and sustainable fabrication of next generation advanced polymers. Given the global threat of petroleum-based plastics processing and disposal, this is an extremely important aspect of the research in this field.

What are the challenges and future developments of the field?

Kerstin: At this moment, we usually try to relate the macroscopic material properties (measured in the lab) with the microscopic environment that cells sense. In my view, we are missing a key piece of information. We need to understand how the macroscopic properties of a material emerge from its molecular composition, topography and hierarchical structure. In combination, all these parameters determine the mechanical properties of a material and, more importantly, what the cells see. In fact, this is not only key for the development of new extracellular matrix mimics. The same questions need to be answered for understanding how nature assembles a wide range of structural and functional materials with outstanding properties, such as spider silk, cellulose composites and nacre. Here, I see a great potential for future collaboration between disciplines.

Matt: There are enormous challenges on the bio-inspiration side of the field involved with transferring design principles extracted from biological materials into synthetic systems. Biology is inherently complex, so there is a common tendency to distil the extracted concept to a single functional group or concept, while often there are collective effects that are lost by this more reductionist approach. On the biological side, a key challenge is ascertaining which are the relevant design principles. On the bio-inspired side, there are challenges in finding appropriate synthetic analogues to mimic the chemical and structural complexity of the natural system. Overcoming this barrier requires cross-disciplinary communication and feedback and is an extremely exciting and active area in our field.

Why and when did you decide to organize a conference on this topic?

Kerstin & Matt: While both working at the Max Planck Institute of Colloids and Interfaces, we quickly realized that the cell biophysics, biomaterials, mechanochemistry and soft matter communities are all interested in very similar questions while using similar methods and theoretical models; however, we had the impression that they hardly interact with each other. We thought of ways to change this and organizing a conference was clearly one way to do it. The first conference with the topic Multiscale Mechanochemistry and Mechanobiology: from molecular mechanisms to smart materials took place in Berlin in 2017. When bringing this idea forward in our respective communities, we immediately realized that we hit a nerve. Now that the conference has taken place for the second time in Montreal in 2019, we really got the feeling that we are starting to create a community around this topic. There will be another follow up conference from August 23-25, 2021 in Berlin (@mcb2021Berlin).

What are the most interesting and representative papers published in PLOS ONE in this field?

Kerstin: The paper Monodisperse measurement of the biotin-streptavidin interaction strength in a well-defined pulling geometry, published by Sedlak et al., is a highly interesting contribution to the field of single-molecule force spectroscopy, which was also presented at the conference. This work highlights the methodological developments in single-molecule force spectroscopy since its very early days. The authors from the Gaub labhave re-measured the well-known streptavidin-biotin interaction, now with a very high level of control over the molecular setup. It clearly shows how far the field has come and also that protein engineering, bioconjugation chemistry, instrumentation development and data analysis all need to go hand in hand to obtain clear and unambiguous experimental results. Clearly, considering a defined molecular setup is not only crucial for this kind of measurement but also for the development of biomimetic materials with controlled mechanical properties.

Sedlak SM, Bauer MS, Kluger C, Schendel LC, Milles LF, Pippig DA, et al. (2017) Monodisperse measurement of the biotin-streptavidin interaction strength in a well-defined pulling geometry. PLoS ONE 12(12): e0188722,https://doi.org/10.1371/journal.pone.0188722

Matt: Accurately detecting and measuring the mechanical forces at play inside living cells is one of the key challenges in the field of mechanobiology, given the small size and dynamic nature of the intracellular environment. However, this information is extremely important for understanding the role of mechanics in regulating cellular functions such as growth, differentiation and proliferation, as well as disease states. In the Nuclei deformation reveals pressure distributions in 3D cell clusters paper from the Ehrlicher group, the authors address this challenge by using fluorescently labelled proteins in the cell nucleus coupled with confocal microscopy to measure compressive pressures within cells and cell clusters. Using this methodology, they explored the effect of cell number and shape of multicellular clusters on the internal compressive pressure within cells, providing potentially important insights for cellular signalling and function. These studies have potential applications in both in vitro and in vivo models, and provide a relatively simple methodology for acquiring intracellular mechanical data.

Khavari A, Ehrlicher AJ (2019) Nuclei deformation reveals pressure distributions in 3D cell clusters. PLoS ONE 14(9): e0221753,https://doi.org/10.1371/journal.pone.0221753

Other PLOS ONE representative papers:

Kerstin Blank studied Biotechnology at the University of Applied Sciences in Jena and obtained her PhDin Biophysics under the supervision of Prof Hermann Gaub at Ludwig-Maximilians Universitt in Munich. After two postdocs at the Universit de Strasbourg and the Katholieke Universiteit Leuven, she became an Assistant Professor at Radboud University in Nijmegen in 2009. In 2014, she moved to the Max Planck Institute of Colloids and Interfaces where she holds the position of a Max Planck Research Group Leader. Her research interests combine biochemistry and single molecule biophysics with the goal of developing molecular force sensors for biological and materials science applications.

Matthew J. Harrington is Canada Research Chair in Green Chemistry and assistant professor in Chemistry at McGill University since 2017. He received his PhD in the lab of J. Herbert Waite from the University of California, Santa Barbara. Afterwards, he was a Humboldt postdoctoral fellow and then research group leader at the Max Planck Institute of Colloids and Interfaces in the Department of Biomaterials. His research interests are focused on understanding biochemical structure-function relationships and fabrication processes of biopolymeric materials and translating extracted design principles for production of sustainable, advanced materials.

Link:
Physical forces at the interface with biology and chemistry - PLoS Blogs

No system is perfect, multi-disciplinary approach will benefit cancer patients: Ayurvedic physician – The New Indian Express

Express News Service

KOCHI: According to researchers and doctors from different systems of medicines gathered at the International Conference on Integrated Oncology (ICIO) 2020, allopathic and complementary medicines can work magic in cancer patients. Homoeopathy and ayurvedic medicines have a greater role to play in treating and curing cancer patients.

A multi-disciplinary approach is required for the cure and management of cancer cases because no system is perfect in the world. By integrating complementary medicines the ultimate beneficiary of the result will be patients, said Dr K M Madhu, ayurvedic physician at Kottakkal Arya Vaidya Sala Hospital, Kochi.

In India, existing medicine systems like ayurveda, yoga and naturopathy, unani, siddha, and homoeopathy can do magic on cancer patients. In ayurveda, we have the three doshas Vata, Pitta, and Kapha, which are believed to create diseases.

We treat to pacify these doshas which are the framework of ayurveda. When you come to a practical integration, all these frameworks may not match together as there may be so many differences between them. The general thing for the integration to happen is that all should accept that their system is not the perfect one. They also lack many things. Self-criticism is required to improve the way you get integrated with other medical systems, said Madhu.Ayurveda can contribute to palliative care. We have Rasayanas which will help in cancer cure. Study on Misraka Sneham, Sathadhouta Ghritham and Viswamritham in managing anorexia in cancer patients have proved good relief in 70 percent of patients we tested, said Madhu.

According to Dr Nilanjana Basu, homoeopathy doctor and researcher at Amity Institute of Molecular Research and Stem Cell Research, Amity University, Noida, homoeopathic medicines can enhance the activity of the normal cells in ones body. Present-day studies are looking into how to kill cancer cells. But what I found different is why do we only focus on the cancer cells. We can protect the normal cells. Conventional medicinal treatments are hard on cancer cells. It should be that way as well. As the patients suffer more, there has to be something that softens and homoeopathy is that part that softens our body and preserve and maintain natural and normal cells, said Nilanjana.Arnica Montana, a homoeopathic medicine, was used for my research in protecting the normal cells when we try to kill the cancer cells. It was proved that the medicine can actually enhance normal cell activity, said Nilanjana.

Link:
No system is perfect, multi-disciplinary approach will benefit cancer patients: Ayurvedic physician - The New Indian Express